Mangoceuticals (MGRX) S-1 16 Aug 24 IPO registration Financial data

Cover

Cover	6 Months Ended
	Jun. 30, 2024
Entity Addresses [Line Items]
Document Type	S-1
Amendment Flag	false
Entity Registrant Name	Mangoceuticals, Inc.
Entity Central Index Key	0001938046
Entity Primary SIC Number	8099
Entity Tax Identification Number	87-3841292
Entity Incorporation, State or Country Code	TX
Entity Address, Address Line One	15110 N. Dallas Parkway
Entity Address, Address Line Two	Suite 600
Entity Address, City or Town	Dallas
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75248
City Area Code	(214)
Local Phone Number	242-9619
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Business Contact [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	15110 N. Dallas Parkway
Entity Address, Address Line Two	Suite 600
Entity Address, City or Town	Dallas
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75248
City Area Code	(214)
Local Phone Number	242-9619
Contact Personnel Name	Jacob D. Cohen

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash	$ 490,243	$ 739,006	$ 682,860
Inventory	14,019	18,501
TOTAL CURRENT ASSETS	517,561	818,460	694,605
NON-CURRENT ASSETS
Property and equipment, net of accumulated depreciation of $28,752 and $3,863		96,129	117,499
Property and equipment	3,313	96,129	117,499
TOTAL NON-CURRENT ASSETS	14,703,324	215,391
OTHER ASSETS
Deposits	16,942	16,942	16,942
Right of use - asset	90,011	119,262	174,241
Intangible assets – acquired patents	14,610,000
OTHER ASSETS (INCLUDING RIGHT OF USE ASSETS)		136,204	191,183
TOTAL OTHER ASSETS	16,942	16,942
TOTAL ASSETS	15,237,827	1,050,793	1,003,287
CURRENT LIABILITIES
Accounts payable and accrued liabilities	718,650	140,765	33,675
Payroll tax liabilities	4,687	6,595	2,717
Right-of-use liability - operating lease	67,428	63,718	56,725
Other liabilities – patent purchase payable	400,000
TOTAL CURRENT LIABILITIES	1,378,265	211,078	260,577
LONG-TERM LIABILITIES
Right-of-use liability - operating lease	30,117	64,961	128,680
TOTAL LONG-TERM LIABILITIES	30,117	64,961	128,680
TOTAL LIABILITIES	1,408,382	276,039	389,257
COMMITMENTS AND CONTINGENCIES (SEE NOTE 11)
STOCKHOLDERS’ EQUITY
Common stock (par value $0.0001, 200,000,000 shares authorized, of which 29,135,451 and 21,419,500 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively)	2,913	2,142	1,337
Stock warrants	514,496
Subscription receivable	(1,000,000)
Additional paid in capital	30,300,213	12,000,785	2,628,449
Accumulated deficit	(15,986,733)	(11,228,173)	(2,015,756)
Accumulated other comprehensive loss	(1,166)
TOTAL STOCKHOLDERS’ EQUITY	13,829,821	774,754	614,030
Non-controlling interest	(376)
TOTAL STOCKHOLDERS’ EQUITY	13,829,445	774,754	614,030
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	15,237,827	1,050,793	1,003,287
Series B Convertible Preferred Stock [Member]
STOCKHOLDERS’ EQUITY
Preferred stock,value
Series C Convertible Preferred Stock [Member]
STOCKHOLDERS’ EQUITY
Preferred stock,value	98
Related Party [Member]
CURRENT ASSETS
Prepaid expenses - related party	13,299	60,953	11,745
CURRENT LIABILITIES
Notes payable to related parties	$ 187,500		89,200
Nonrelated Party [Member]
CURRENT LIABILITIES
Notes payable to related parties			$ 78,260

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2024	Mar. 28, 2024	Dec. 31, 2023	Dec. 31, 2022
Accumulated depreciation	$ 1,749		$ 28,752	$ 3,863
Common stock, par value	$ 0.0001		$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000		200,000,000	200,000,000
Common stock, shares issued	29,135,451		21,419,500	13,365,000
Common stock, shares outstanding	29,135,451		21,419,500	13,365,000
PreferredStock, par value	$ 0.0001		$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000		10,000,000	10,000,000
Series B Convertible Preferred Stock [Member]
PreferredStock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	6,000	6,000	6,000
Preferred stock, shares issued	2,145		0
Preferred stock, shares outstanding	2,145		0
Series C Convertible Preferred Stock [Member]
PreferredStock, par value	$ 0.0001		$ 0.0001
Preferred stock, shares authorized	6,250,000		6,250,000
Preferred stock, shares issued	980,000		0
Preferred stock, shares outstanding	980,000		0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Revenues
Revenues	$ 163,163	$ 141,237	$ 377,258	$ 241,959	$ 731,493	$ 8,939
Cost of revenues	29,665	25,592	50,460	49,345	154,900	4,089
Cost of revenues - related party	63,706	28,515	109,608	48,285	145,092
Gross profit	69,792	87,130	217,190	144,329	431,501	4,850
Operating expenses
General and administrative expenses	850,704	567,655	1,622,662	1,951,614	3,319,417	1,643,572
Salary and benefits	259,105	374,396	552,314	396,094	977,890
Advertising and marketing	229,244	797,263	1,081,627	912,997	2,097,505	352,860
Investor relations	40,000	90,500	183,000	519,465	1,100,465
Stock based compensation	859,380	549,574	1,313,845	1,215,542	2,155,114
Total operating expenses	2,238,433	2,379,388	4,753,448	4,995,712	9,650,391	1,996,432
Loss from operations	(2,168,641)	(2,292,258)	(4,536,258)	(4,851,383)	(9,218,890)	(1,991,582)
Other expense
Other income					(6,473)
Imputed interest - related party		(8,233)		(6,473)		6,473
Interest expense - amortization on discount	222,678		222,678
Total other expense	222,678	(8,233)	222,678	(6,473)	(6,473)	6,473
Loss before income taxes	(2,391,319)	(2,284,025)	(4,758,936)	(4,844,910)	(9,212,417)	(1,998,055)
Income taxes
Net loss	(2,391,319)	(2,284,025)	(4,758,936)	(4,844,910)	(9,212,417)	(1,998,055)
Net loss attributed to non-controlling interest	(340)		(376)
Net loss attributed to Mangoceuticals, Inc.	$ (2,390,979)	$ (2,284,025)	$ (4,758,560)	$ (4,844,910)	$ (9,212,417)	$ (1,998,055)
Basic and diluted loss per share
Basic loss per share	$ (0.09)	$ (0.14)	$ (0.19)	$ (0.33)	$ (0.57)	$ (0.19)
Diluted loss per share	$ (0.09)	$ (0.14)	$ (0.19)	$ (0.33)	$ (0.57)	$ (0.19)
Weighted average number of shares outstanding
Basic	26,099,532	15,772,348	24,577,289	14,500,230	16,113,029	10,798,083
Diluted	26,099,532	15,772,348	24,577,289	14,500,230	16,113,029	10,798,083

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)	Preferred Stock [Member] Preferred Class B [Member]	Preferred Stock [Member] Preferred Class C [Member]	Common Stock [Member]	Warrant [Member]	Subscription Receivable [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2021			$ 800			$ 181	$ (17,701)			$ (16,720)
Balance, shares at Dec. 31, 2021			8,000,000
Issuance of common stock for services			$ 337			539,728				540,065
Issuance of common stock for services, shares			3,365,000
Issuance of units for cash			$ 200			1,999,800				2,000,000
Balance, shares			2,000,000
Options and warrants vested for services						234,088				234,088
Warrants for services cancelled						(151,821)				(151,821)
Imputed interest						6,473				6,473
Net loss							(1,998,055)			(1,998,055)
Balance at Dec. 31, 2022			$ 1,337			2,628,449	(2,015,756)			614,030
Balance, shares at Dec. 31, 2022			13,365,000
Balance at Dec. 31, 2022			$ 1,337			2,628,449	(2,015,756)			614,030
Issuance of common stock for services			$ 70			699,930				700,000
Issuance of common stock for services, shares			700,000
Issuance of common stock for cash			$ 125			4,999,875				5,000,000
Issuance of common stock for cash, shares			1,250,000
Options and warrants vested for services						64,271				64,271
Imputed interest						1,760				1,760
Net loss							(2,560,885)			(2,560,885)
Balance, shares at Mar. 31, 2023			15,315,000
Balance at Mar. 31, 2023			$ 1,532			8,394,285	(4,576,641)			3,819,176
Balance at Dec. 31, 2022			$ 1,337			2,628,449	(2,015,756)			614,030
Balance, shares at Dec. 31, 2022			13,365,000
Balance at Dec. 31, 2022			$ 1,337			2,628,449	(2,015,756)			614,030
Translation adjustment
Net loss										(4,844,910)
Balance, shares at Jun. 30, 2023			16,714,500
Balance at Jun. 30, 2023			$ 1,671			9,861,684	(6,860,666)			3,002,689
Balance at Dec. 31, 2022			$ 1,337			2,628,449	(2,015,756)			614,030
Balance, shares at Dec. 31, 2022			13,365,000
Balance at Dec. 31, 2022			$ 1,337			2,628,449	(2,015,756)			614,030
Issuance of common stock for services			$ 178			1,530,473				1,530,651
Issuance of common stock for services, shares			1,780,000
Issuance of common stock for cash			$ 525			6,199,475				6,200,000
Issuance of common stock for cash, shares			5,250,000
Imputed interest related party loan repayment						(6,473)				(6,473)
Options and warrants vested for services						624,463				624,463
Warrants exercised			$ 102			1,024,398				1,024,500
Balance, shares			1,024,500
Net loss							(9,212,417)			(9,212,417)
Balance at Dec. 31, 2023			$ 2,142			12,000,785	(11,228,173)			774,754
Balance, shares at Dec. 31, 2023			21,419,500
Balance at Dec. 31, 2023			$ 2,142			12,000,785	(11,228,173)			774,754
Balance, shares at Mar. 31, 2023			15,315,000
Balance at Mar. 31, 2023			$ 1,532			8,394,285	(4,576,641)			3,819,176
Issuance of common stock for services			$ 37			386,963				387,000
Issuance of common stock for services, shares			375,000
Issuance of common stock for cash			$ 102			1,024,398				1,024,500
Issuance of common stock for cash, shares			1,024,500
Options and warrants vested for services						64,271				64,271
Translation adjustment
Imputed interest						(8,233)				(8,233)
Net loss							(2,284,025)			(2,284,025)
Balance, shares at Jun. 30, 2023			16,714,500
Balance at Jun. 30, 2023			$ 1,671			9,861,684	(6,860,666)			3,002,689
Balance, shares at Dec. 31, 2023			21,419,500
Balance at Dec. 31, 2023			$ 2,142			12,000,785	(11,228,173)			774,754
Issuance of common stock for services			$ 160			416,340				416,500
Issuance of common stock for services, shares			1,600,000
Issuance of common stock for cash			$ 60			179,940				180,000
Issuance of common stock for cash, shares			600,000
Options and warrants vested for services						37,965				37,965
Translation adjustment								(70)		(70)
Net loss							(2,367,581)		(36)	(2,367,617)
Balance, shares at Mar. 31, 2024			23,619,500
Balance at Mar. 31, 2024			$ 2,362			12,635,030	(13,595,754)	(70)	(36)	(958,468)
Balance at Dec. 31, 2023			$ 2,142			12,000,785	(11,228,173)			774,754
Balance, shares at Dec. 31, 2023			21,419,500
Balance at Dec. 31, 2023			$ 2,142			12,000,785	(11,228,173)			774,754
Translation adjustment										(1,166)
Net loss										(4,758,936)
Balance at Jun. 30, 2024										13,829,821
Balance, shares at Jun. 30, 2024	2,145	980,000	29,135,451
Balance at Jun. 30, 2024		$ 98	$ 2,913	514,496	(1,000,000)	30,300,213	(15,986,733)	(1,166)	(376)	13,829,445
Balance, shares at Mar. 31, 2024			23,619,500
Balance at Mar. 31, 2024			$ 2,362			12,635,030	(13,595,754)	(70)	(36)	(958,468)
Issuance of common stock for services			$ 264			808,136				808,400
Issuance of common stock for services, shares			2,642,308
Issuance of preferred stock B for cash				514,496	(1,000,000)	1,985,504				1,500,000
Issuance of preferred stock B for cash, shares	2,500
Amortization of discount on preferred stock						222,678				222,678
Issuance of preferred stock C for patent acquisition		$ 98				14,209,902				14,210,000
Issuance of preferred stock C for patent acquisition, shares		980,000
Issuance of common stock for cash			$ 95			388,175				388,270
Issuance of common stock for cash, shares			950,000
Conversion of preferred stock B for common stock						(390,500)				(390,500)
Conversion of preferred stock B for common stock, shares	(355)
Issuance of common stock for conversion of preferred stock B			$ 192			390,308				390,500
Issuance of common stock for conversion of preferred stock B, shares			1,923,643
Options and warrants vested for services						50,980				50,980
Translation adjustment								(1,096)		(1,096)
Net loss							(2,390,979)		(340)	(2,391,319)
Balance at Jun. 30, 2024										13,829,821
Balance, shares at Jun. 30, 2024	2,145	980,000	29,135,451
Balance at Jun. 30, 2024		$ 98	$ 2,913	$ 514,496	$ (1,000,000)	$ 30,300,213	$ (15,986,733)	$ (1,166)	$ (376)	$ 13,829,445

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (4,758,936)	$ (4,844,910)	$ (9,212,417)	$ (1,998,055)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	9,429	12,306	24,889	3,863
Issuance of common stock for services	1,224,900	1,087,000	1,530,651	540,065
Imputed interest expense		(6,473)		6,473
Other income			(6,473)
Options vested for stock-based compensation	88,945	128,542	624,463	234,088
Loss on sale of assets	18,387
Amortization of discount on preferred stock	222,678
Warrants for service cancelled				(151,821)
(Increase) decrease in operating assets:
Rent Deposits				(16,942)
Inventory	4,482	(23,494)	(18,501)
Prepaid expenses	47,654	(41,015)	(49,208)	(11,745)
Operating lease right of use asset	29,251	27,082	54,979	(174,241)
(Decrease) increase in operating liabilities:
Accounts payable and accrued liabilities			107,090	33,675
Operating lease right of use liabilities	(31,134)	(27,862)	(56,726)	185,405
Payroll tax liabilities	(1,908)	3,408	3,878	2,717
NET CASH USED IN OPERATING ACTIVITIES	(2,568,367)	(3,588,886)	(6,997,375)	(1,346,518)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment		(3,519)	(3,519)	(43,102)
Sale of property and equipment	65,000
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	65,000	(3,519)	(3,519)	(43,102)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from borrowings on notes payable to related parties	187,500			75,000
Proceeds from sales of preferred stock for cash	1,500,000
Proceeds from exercise of warrants		1,024,500
Repayment on notes payable		(78,260)	(78,260)
Repayment on notes payable - related party		(89,200)	(89,200)	(25,070)
Proceeds from exercise of warrants			1,024,500
Proceeds from sales of common stock for cash	568,270	5,000,000	6,200,000	2,000,000
NET CASH PROVIDED BY FINANCING ACTIVITIES	2,255,770	5,857,040	7,057,040	2,049,930
End of period	(247,597)	2,264,635	56,146	660,310
CASH AND CASH EQUIVALENTS:
Beginning of period	739,006	682,860	682,860	22,550
Effects of currency translation on cash and cash equivalents	(1,166)
End of period	490,243	2,947,495	739,006	682,860
Supplemental disclosure of cash flow information:
Cash paid for income taxes
Cash paid for interest
Supplemental schedule of non-cash investing and financing activities:
Issuance of Series C Convertible Preferred for patent acquisition	14,610,000
Series B Convertible Preferred converted to common stock	390,500
Nonrelated Party [Member]
(Decrease) increase in operating liabilities:
Accounts payable and accrued liabilities	577,885	96,530
Related Party [Member]
(Decrease) increase in operating liabilities:
Accounts payable and accrued liabilities

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Net loss attributable to Mangoceuticals, Inc.	$ (2,391,319)	$ (2,284,025)	$ (4,758,936)	$ (4,844,910)
Other comprehensive expense
Foreign currency adjustments	(1,096)		(1,166)
Comprehensive loss	(2,392,415)	(2,284,025)	(4,760,102)	(4,844,910)
Other comprehensive expense
Net loss attributed to non-controlling interest	(340)		(376)
Comprehensive loss attributable to Mangoceuticals, Inc.	$ (2,392,075)	$ (2,284,025)	$ (4,759,726)	$ (4,844,910)

ORGANIZATION AND DESCRIPTION OF

ORGANIZATION AND DESCRIPTION OF THE BUSINESS	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND DESCRIPTION OF THE BUSINESS	NOTE 1 – ORGANIZATION AND DESCRIPTION OF THE BUSINESS Mangoceuticals, Inc. (“ Mangoceuticals Company ED Mango Grow. FDA www.MangoRx.com Initial Public Offering. IPO 1,250,000 4.00 4.35 Resale Prospectus 4,765,000 2,000,000 1.00 On December 15, 2023, we entered into another underwriting agreement (the “ Underwriting Agreement Boustead Underwriters 4,000,000 0.30 600,000 Follow On Offering The Follow On Offering closed on December 19, 2023. As a result, the Company sold 4,000,000 1.2 The net proceeds to the Company from the Offering, after deducting the underwriting discounts and commissions and offering expenses, were approximately $ 1.0 On December 19, 2023, pursuant to the Underwriting Agreement, the Company issued a common stock purchase warrant to Boustead for the purchase of 280,000 0.38 On January 18, 2024, the Underwriters notified the Company that they were exercising their over-allotment option in full to purchase an additional 600,000 600,000 160,000 4,600,000 On January 22, 2024, pursuant to the Underwriting Agreement, the Company also issued a common stock purchase warrant to Boustead for the purchase of 42,000 0.375 On April 5, 2024 (the “ Initial Closing Date SPA Purchaser 1,500 Series B Preferred Stock 1,650,000 Initial Warrants 3,300,000 1,500,000 500 Initial Closing Shares 500,000 Also on the Initial Closing Date, the Company entered into an Equity Purchase Agreement (the “ ELOC 25,000,000 Maximum Amount Financing 1,000,000 Commitment Shares 0.2149 214,900 On April 26, 2024, the Company partially closed a planned second closing under the SPA (the “ Second Closing 150,000 150 On May 17, 2024, the Company closed the remaining portion of the Second Closing whereby the Purchaser paid $ 100,000 100 On April 28, 2024, the Company and the Purchaser entered into an Omnibus Amendment Agreement No. 1 (the “ Amendment SCHEDULE OF SHARE PURCHASE AGREEMENT # Initial Stated Warrants Closing Date Aggregate Initial Closing $ 550,000 3,300,000 Initial Closing Date $ 500,000 Initial Closing Amount Second Closing $ 275,000 On or before June 30, 2024 Second Closing Date $ 250,000 Second Closing Amount Third Closing $ 825,000 1,500,000 On or before June 30, 2024 $ 750,000 Third Closing Amount Fourth Closing $ 1,100,000 Such date as is no later than 180 days (the “ Fourth Closing Date Securities Act $ 1,000,000.00 Fourth Closing Amount Total $ 2,750,000 4,800,000 $ 2,500,000 On June 28, 2024 (the “ Third Closing Date 750 Third Closing Shares 1,000,000 0.50 500,000 1.00 Additional Warrants Warrants Warrant Shares As described in the table above, the sale of an additional 1,000 On April 24, 2024, the Company entered into a Patent Purchase Agreement (the “ IP Purchase Agreement Intramont Patents 20,000,000 980,000 Series C Preferred Stock 20.00 19,600,000 400,000 (i) with $200,000 payable on or before June 30, 2024, which was timely paid, (ii) $100,000 payable on or before August 31, 2024, and (iii) $100,000 payable on or before November 30, 2024. The Company purchased the Patents and assigned the Patents to its newly formed wholly-owned subsidiary, MangoRx IP Holdings, LLC, a Texas limited liability company. MangoRx Mexico 98 MangoRx UK Limited 100	NOTE 1 – ORGANIZATION AND DESCRIPTION OF THE BUSINESS Mangoceuticals, Inc. (“Mangoceuticals” or the “Company”), was incorporated in the State of a Texas on October 7, 2021, with the intent of focusing on developing, marketing, and selling a variety of men’s wellness products and services via a telemedicine platform. To date, the Company has identified men’s wellness telemedicine services and products as a growing sector in the most recent years and especially related to the areas of erectile dysfunction (“ED”), hair loss and testosterone replacement or enhancement therapies. In this regard, Mangoceuticals has developed and is commercially marketing a new brand of ED products under the brand name “Mango” and a new brand of hair loss products under the brand name “Grow.” These products are produced at a compounding pharmacy using a proprietary combination of U.S. Food and Drug Administration (“FDA”) approved ingredients and is available to patients on the determination of a prescribing physician that the compounded drug is necessary for the individual patient. Mangoceuticals is currently marketing and selling these branded ED and hair loss products exclusively online via its website at www.MangoRx.com Initial Public Offering. 1,250,000 4.00 4.35 4,765,000 2,000,000 1.00

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation US GAAP Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. Cash Equivalents Highly liquid investments with original maturities of three months or less are considered cash equivalents. The Company maintains the majority of its cash accounts at a commercial bank. The Federal Deposit Insurance Corporation (“ FDIC 250,000 no Principles of Consolidation The accompanying consolidated financial statements include the accounts of Mangoceuticals, Inc. and all wholly and majority-owned subsidiaries. All significant intercompany transactions and balances between the Company and its subsidiaries are eliminated upon consolidation. Wholly-owned subsidiaries: MangoRx UK Limited MangoRx IP Holdings, LLC Majority-owned subsidiaries: The Company owns 98 Non-Controlling Interest The Company owns 98 Segment Reporting The Company operates as one segment, in which management uses one measure of profitability, and all of the Company’s assets are located in the United States of America. The Company does not operate separate lines of business or separate business entities with respect to any of its product candidates. Accordingly, the Company does not have separately reportable segments. Income Taxes The Company accounts for income taxes in accordance with ASC 740, Accounting for Income Taxes, as clarified by ASC 740-10, Accounting for Uncertainty in Income Taxes. Under this method, deferred income taxes are determined based on the estimated future tax effects of differences between the financial statement and tax basis of assets and liabilities given the provisions of enacted tax laws. Deferred income tax provisions and benefits are based on changes to the assets or liabilities from year to year. In providing for deferred taxes, the Company considers tax regulations of the jurisdictions in which the Company operates, estimates of future taxable income, and available tax planning strategies. If tax regulations, operating results or the ability to implement tax-planning strategies vary, adjustments to the carrying value of deferred tax assets and liabilities may be required. Valuation allowances are recorded related to deferred tax assets based on the “more likely than not” criteria of ASC 740. ASC 740-10 requires that the Company recognize the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the “more-likely-than-not” threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. Intangible Assets Intangible assets that have indefinite useful life are patents as of June 30,2024. The Company evaluates indefinite-lived intangible assets each reporting period to determine whether events and circumstances continue to support indefinite useful lives. The value of indefinite-lived intangible assets is not amortized, but tested for impairment annually or whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. As such, no Foreign Currency Translation and transaction The Company’s principal country of operations is United States. The financial position and results of its operations are determined using U.S. Dollars (“US$”), the local currency, as the functional currency. The Company’s financial statements are reported using the U.S. Dollars (“US$” or “$”). The results of operations and the statements of cash flows denominated in foreign currency are translated at the average rate of exchange during the reporting period. Assets and liabilities denominated in foreign currencies at the balance sheet date are translated at the applicable rates of exchange in effect at that date. The equity denominated in the functional currency is translated at the historical rate of exchange at the time of capital contribution. Because cash flows are translated based on the average translation rate, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheets. Translation adjustments arising from the use of different exchange rates from period to period are included as a separate component of accumulated other comprehensive income (loss) included in statements of changes in shareholders’ equity. Gains and losses from foreign currency transactions are included in the Company’s statements of operations and comprehensive income (loss). The following table outlines the currency exchange rates that were used in preparing the financial statements: SCHEDULE OF FOREIGN CURRENCY TRANSLATION AND TRANSACTION June 30, June 30, 2024 2023 Period-end spot rate US$ 1 0.54 N/A Average rate US$ 1 0.58 N/A Net Loss Per Common Share We compute net loss per share in accordance with ASC 260, Earning per Share EPS 2,366,667 6,185,000 no 2,650,000 1,343,000 no Use of Estimates and Assumptions The preparation of financial statements in accordance with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results can, and in many cases will, differ from those estimates. Fair Value of Financial Instruments The Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with FASB ASC 820, Fair Value Measurement ASC 820 Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The following tables summarize our financial instruments measured at fair value as of June 30, 2024 and December 31, 2023. SCHEDULE OF FINANCIAL INSTRUMENTS MEASUREMENT AT FAIR VALUE Level 1 Level 2 Level 3 Fair Value Measurements at June 30, 2024 Level 1 Level 2 Level 3 Assets Cash $ 490,243 $ - $ - Total assets 490,243 - - Liabilities Total liabilities - - - Fair value, net asset (liability) $ 490,243 $ - $ - Level 1 Level 2 Level 3 Fair Value Measurements at December 31, 2023 Level 1 Level 2 Level 3 Assets Cash $ 739,006 $ - $ - Total assets 739,006 - - Liabilities Total liabilities - - - Fair value, net asset (liability) $ 739,006 $ - $ - Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from the disposition is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of three ( 3 5 Concentration and Risks The Company’s operations are subject to risks including financial, operational, regulatory and other risks including the potential risk of business failure. For the six months ended June 30, 2024 and 2023, the Company had no significant revenue from continuing operations which were derived from a single or a few major customers. Black-Scholes Option Pricing Model The Company uses a Black-Scholes option pricing model to determine the fair value of warrants and options issued. Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the effect of recently issued standards that are not yet effective will not have a material effect on its financial position or results of operations upon adoption. In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures (Topic 280). This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”) and included within each reported measure of a segment’s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment’s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is also permitted. This ASU will likely result in us including the additional required disclosures when adopted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending December 31, 2024. In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is also permitted for annual financial statements that have not yet been issued or made available for issuance. This ASU will result in the required additional disclosures being included in our consolidated financial statements, once adopted. Related Parties The Company follows subtopic 850-10 of FASB ASC 850, Related Party Pursuant to Section 850-10-20, the related parties include a. affiliates of the Company; b. Entities for which investments in their equity securities would be required, absent the election of the fair value option under the guidance of Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company; f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g. other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests. The consolidated financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of financial statements is not required in those statements. The disclosures shall include: a. the nature of the relationship(s) involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement. Material related party transactions have been identified in Notes 3, 7 and 9 in the notes to consolidated financial statements. Stock-Based Compensation The Company recognizes compensation costs to employees under FASB ASC 718 Compensation - Stock Compensation ASC 718 Revenue Recognition The Company follows the provisions of ASC 606. Revenue from Contracts with Customer for recording and recognizing revenue from customers The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services and has met its performance obligation. For revenue generated through its online platform, the Company defines its customer as an individual who purchases products or services through websites. The transaction price in the Company’s contracts with customers is the total amount of consideration to which the Company expects to be entitled in exchange for transferring products or services to the customer. The Company’s contracts that contain prescription products issued as the result of a consultation include two performance obligations: access to (i) products and (ii) consultation services. The Company’s contracts for prescription refills have a single performance obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised product to the customer and, in contracts that contain services, by the provision of consultation services to the customer. The Company satisfies its performance obligation for products at a point in time, which is upon delivery of the products to a third-party carrier. The Company satisfies its performance obligation for services over the period of the consultation service, which is typically a few days. The customer obtains control of the products and services upon the Company’s completion of its performance obligations. The Company has entered into a Physician Services Agreement with BrighterMD, LLC dba Doctegrity (“ Doctegrity Additionally, the Company has entered into a Master Services Agreement and Statement of Work with Epiq Scripts, LLC (“ Contracted Pharmacy The Company accounts for shipping activities, consisting of direct costs to ship products performed after the control of a product has been transferred to the customer, in cost of revenue. Inventories Inventories are stated at the lower of cost or net realizable value with cost being determined on a first-in, first-out (“ FIFO no Marketing and Advertising The Company follows the policy of charging the costs of marketing and advertising to expense as incurred. The Company charged $ 1,081,627 912,997 Subsequent Events The Company follows the guidance in Section 855-10-50 of FASB ASC 855, Subsequent Events	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation Cash Equivalents Highly liquid investments with original maturities of three months or less are considered cash equivalents. The Company maintains the majority of its cash accounts at a commercial bank. The Federal Deposit Insurance Corporation (“FDIC”) insures the total cash balance up to $ 250,000 no Income Taxes The Company is a taxable entity and recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Income taxes are provided in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740, Income Taxes Net Loss Per Common Share We compute net loss per share in accordance with ASC 260, Earning per Share 2,650,000 1,343,000 1,250,000 2,000,000 Use of Estimates and Assumptions The preparation of financial statements in accordance with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results can, and in many cases will, differ from those estimates. Fair Value of Financial Instruments The Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with FASB ASC 820, Fair Value Measurement Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one more significant inputs or significant value drivers are unobservable. The following tables summarize our financial instruments measured at fair value as of December 31, 2023 and 2022. SCHEDULE OF FINANCIAL INSTRUMENTS MEASUREMENT AT FAIR VALUE Level 1 Level 2 Level 3 Fair Value Measurements at December 31, 2023 Level 1 Level 2 Level 3 Assets Cash $ 739,006 $ - $ - Total assets 739,006 - - Liabilities Total liabilities - - - Fair value, net asset (liability) $ 739,006 $ - $ - Level 1 Level 2 Level 3 Fair Value Measurements at December 31, 2022 Level 1 Level 2 Level 3 Assets Cash $ 682,860 $ - $ - Total assets 682,860 - - Liabilities Total liabilities - - - Fair value, net asset (liability) $ 682,860 $ - $ - Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from the disposition is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of three ( 3 5 Concentration and Risks The Company’s operations are subject to risks including financial, operational, regulatory and other risks including the potential risk of business failure. For the years ended December 31, 2023 and 2022, the Company had no significant revenue from continuing operations which were derived from a single or a few major customers. Black-Scholes Option Pricing Model The Company uses a Black-Scholes option pricing model to determine the fair value of warrants and options issued. Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the effect of recently issued standards that are not yet effective will not have a material effect on its financial position or results of operations upon adoption. In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40) ASU 2020-06 Related Parties The Company follows subtopic 850-10 of FASB ASC 850, Related Party Disclosures for the identification of related parties and disclosure of related party transactions. Pursuant to Section 850-10-20, the related parties include a. affiliates of the Company; b. Entities for which investments in their equity securities would be required, absent the election of the fair value option under the guidance of Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company; f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g. other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests. The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of financial statements is not required in those statements. The disclosures shall include: a. the nature of the relationship(s) involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement. Material related party transactions have been identified in Notes 3, 6 and 8 in the notes to financial statements. Stock-Based Compensation The Company recognizes compensation costs to employees under FASB ASC 718 Compensation - Stock Compensation (“ASC 718”). Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include stock options and warrants. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option and warrant grant. Revenue Recognition The Company follows the provisions of ASC 606. Revenue from Contracts with Customer for recording and recognizing revenue from customers The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services and has met its performance obligation. For revenue generated through its online platform, the Company defines its customer as an individual who purchases products or services through websites. The transaction price in the Company’s contracts with customers is the total amount of consideration to which the Company expects to be entitled in exchange for transferring products or services to the customer. The Company’s contracts that contain prescription products issued as the result of a consultation include two performance obligations: access to (i) products and (ii) consultation services. The Company’s contracts for prescription refills have a single performance obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised product to the customer and, in contracts that contain services, by the provision of consultation services to the customer. The Company satisfies its performance obligation for products at a point in time, which is upon delivery of the products to a third-party carrier. The Company satisfies its performance obligation for services over the period of the consultation service, which is typically a few days. The customer obtains control of the products and services upon the Company’s completion of its performance obligations. The Company has entered into a Physician Services Agreement with BrighterMD, LLC dba Doctegrity (“Doctegrity”) to provide online telemedicine technology services to the Company. The Company accounts for service revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company determines which providers provide the consultation to the customer; (ii) the Company is primarily responsible for the satisfactory fulfillment and acceptability of the services; (iii) the Company incurs costs for consultation services even for visits that do not result in a prescription and the sale of products; and (iv) the Company, at its sole discretion, sets all listed prices charged on its websites for products and services. Additionally, the Company has entered into a Master Services Agreement and Statement of Work with Epiq Scripts, LLC (“Contracted Pharmacy”), which is a related party, to provide pharmacy and compounding services to the Company to fulfill its promise to customers for contracts that include sale of prescription products and to fill prescriptions that are ordered by the Company’s customers for fulfillment through the Company’s websites. The Company accounts for prescription product revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company has sole discretion in determining which Contracted Pharmacy fills a customer’s prescription; (ii) Contracted Pharmacy fills the prescription based on fulfillment instructions provided by the Company, including using the Company’s branded packaging for generic products; (iii) the Company is primarily responsible to the customer for the satisfactory fulfillment and acceptability of the order, and; (iv) the Company, at its sole discretion, sets all listed prices charged on its websites for products and services. The Company accounts for shipping activities, consisting of direct costs to ship products performed after the control of a product has been transferred to the customer, in cost of revenue. Inventories Inventories are stated at the lower of cost or net realizable value with cost being determined on a first-in, first-out (“FIFO”) basis. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. During the years ended December 31, 2023 and 2022, there were no Marketing and Advertising The Company follows the policy of charging the costs of marketing and advertising to expense as incurred. The Company charged $ 2,097,505 352,860 Subsequent Events The Company follows the guidance in Section 855-10-50 of FASB ASC 855, Subsequent Events

PREPAID EXPENSES-RELATED PARTIE

PREPAID EXPENSES-RELATED PARTIES	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Prepaid Expenses-related Parties
PREPAID EXPENSES-RELATED PARTIES	NOTE 3 – PREPAID EXPENSES-RELATED PARTIES During the six months ended June 30, 2024 and the year ended December 31, 2023, and in association with the Master Services Agreement and Statement of Work with our related party Contracted Pharmacy, the Company prepays the related party Contracted Pharmacy as a retainer to be credited towards future product sales. As of June 30, 2024 and December 31, 2023, the balance was $ 13,299 60,953	NOTE 3 – PREPAID EXPENSES-RELATED PARTIES During the year ended December 31, 2023, and in association with the Master Services Agreement and Statement of Work with our related party Contracted Pharmacy, the Company prepays the related party Contracted Pharmacy as a retainer to be credited towards future product sales. As of December 31, 2023 and 2022, the balance was $ 60,953 11,745 Additionally, the Company signed a lease agreement for office space, effective October 1, 2022, which included an initial security deposit of $ 16,942

INVENTORY

INVENTORY	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
INVENTORY	NOTE 5 – INVENTORY During the six months ended June 30, 2024 and the year ended December 31, 2023, the Company purchased inventories related to promotional merchandise intended to be sold online. As of June 30, 2024 and December 31, 2023, the inventory balance was $ 14,019 18,501	NOTE 4 – INVENTORY During the years ended December 31, 2023 and 2022, the Company purchased inventories related to promotional merchandise intended to be sold online. As of December 31, 2023 and 2022, the inventory balance was $ 18,501 0

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	NOTE 6 – PROPERTY, PLANT AND EQUIPMENT During the six months ended June 30, 2024 and 2023, the Company acquired computers and office equipment totaling $ 0 3,519 1,749 6,082 119,819 65,000 18,837 3,313 96,129 SCHEDULE OF PROPERTY PLANT AND EQUIPMENT June 30, 2024 December 31, 2023 Computers 5,062 5,062 Equipment 119,819 119,819 Less accumulated depreciation: (1,749 ) (28,752 ) Disposed equipment (119,819 ) 119,819 Property and equipment, net 3,313 96,129	NOTE 5 – PROPERTY, PLANT AND EQUIPMENT During the year ended December 31, 2023, the Company acquired computers and office equipment totaling $3,519. Depreciation for the year ended December 31, 2023 and 2022 was $ 24,889 3,863 96,129 117,499 SCHEDULE OF PROPERTY PLANT AND EQUIPMENT December 31, 2023 December 31, 2022 Computers 5,062 5,062 Equipment 119,819 116,300 Less accumulated depreciation: (28,752 ) (3,863 ) Property and equipment, net 96,129 117,499

LOANS FROM RELATED PARTIES

LOANS FROM RELATED PARTIES	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Related Party Transactions [Abstract]
LOANS FROM RELATED PARTIES	NOTE 7 – LOANS FROM RELATED PARTIES On December 10, 2021 and March 18, 2022, the Company received advances of $ 39,200 50,000 89,200 AMIH Cohen Enterprises SPA 8,000,000 80 90,000 89,200 On June 29, 2022, the Company received an advance of $ 25,000 25,000 89,200 0 8 8,232 On March 1, 2024, the Company borrowed $ 37,500 On March 18, 2024, the Company borrowed $ 50,000 On April 1, 2024, the Company borrowed $ 100,000 For additional information on related party prepaid expenses see Note 3.	NOTE 6 – LOANS FROM RELATED PARTIES On December 10, 2021 and March 18, 2022, the Company received advances of $ 39,200 50,000 89,200 8,000,000 80 90,000 89,200 On June 29, 2022, the Company received an advance of $ 25,000 25,000 89,200 0 89,200 8 8,232 On December 10, 2021, the Company received an advance of $ 70 0 70 8 For additional information on related party prepaid expenses see Note 3.

NOTES PAYABLE

NOTES PAYABLE	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 8 – NOTES PAYABLE On November 18, 2022, the Company entered into a note payable with a vendor for the purchase of equipment in the amount of $ 78,260 5,000 31,630 63,260 0	NOTE 7 – NOTES PAYABLE On November 18, 2022, the Company entered into a note payable with a vendor for the purchase of equipment in the amount of $ 78,260 5,000 31,630 63,260 0 78,260

CAPITAL STOCK

CAPITAL STOCK	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Equity [Abstract]
CAPITAL STOCK	NOTE 9 – CAPITAL STOCK Preferred Stock The Company is authorized to issue up to 10,000,000 blank check 0.0001 Series B Convertible Preferred Stock On March 28, 2024 and amended on June 27, 2024, the Company designated 6,000 0.0001 Series B Preferred Stock 1,100 Stated Value 2,145 0 On April 5, 2024, we agreed to definitive terms on a Securities Purchase Agreement dated April 4, 2024, with an institutional accredited investor, pursuant to which the Company agreed to sell to the Purchaser, and the Purchaser agreed to purchase from the Company, 1,500 1,650,000 3,300,000 1,500,000 500 500,000 On April 26, 2024, the Company partially closed a planned second closing under the SPA whereby the Purchaser paid $ 150,000 150 On May 17, 2024, the Company closed the remaining portion of the Second Closing whereby the Purchaser paid $ 100,000 100 On April 28, 2024, the Company and the Purchaser entered into an Omnibus Amendment Agreement No. 1, which amended the SPA to, adjust the closings which were to take place under the SPA as follows: SCHEDULE OF SHARE PURCHASE AGREEMENT # Initial Stated Warrants Closing Date Aggregate Initial Closing $ 550,000 3,300,000 Initial Closing Date $ 500,000 Second Closing $ 275,000 On or before June 30, 2024 $ 250,000 Third Closing $ 825,000 1,500,000 On or before June 30, 2024 $ 750,000 Fourth Closing $ 1,100,000 Such date as is no later than 180 days after the shares of Common Stock issuable in respect of the Series B Preferred Stock sold in each of the Initial Closing, Second Closing, the Third Closing, and the Fourth Closing have been registered under the Securities Act, subject to any limitations pursuant to Rule 415 $ 1,000,000.00 Total $ 2,750,000 4,800,000 $ 2,500,000 On June 28, 2024, the Company sold the Purchaser 750 1,000,000 0.50 500,000 1.00 As described in the table above, the sale of an additional 1,000 On May 21, 2024, 50 55,000 270,936 0.203 On May 22, 2024, 155 170,500 839,901 0.203 On May 24, 2024, 150 165,000 812,807 0.203 6% Series C Convertible Cumulative Preferred Stock On April 18, 2024, the Company designated 6,250,000 0.0001 Series C Preferred Stock 980,000 0 On April 24, 2024, the Company entered into a Patent Purchase Agreement, with Intramont Technologies, Inc. Pursuant to the IP Purchase Agreement, the Company purchased certain patents and patent applications owned by Intramont, related to prevention of infections, including the common cold, respiratory diseases, and orally transmitted diseases such as human papillomavirus (HPV), in consideration for $ 20,000,000 980,000 20.00 19,600,000 400,000 (i) with $200,000 payable on or before June 30, 2024, (ii) $100,000 payable on or before August 31, 2024, and (iii) $100,000 payable on or before November 30, 2024. Common Stock The Company is authorized to issue 200,000,000 0.0001 29,135,451 21,419,500 On January 3, 2023, we entered into a Consulting Agreement with DojoLabs Group, Inc. (“ DojoLabs 100,000 50,000 1.00 100,000 On January 6, 2023, we entered into a Consulting Agreement with Bethor, Ltd. (“ Bethor 250,000 1.00 250,000 On January 6, 2023, the Company established an advisory board (the “ Advisory Board Advisory Board Charter In connection with the establishment of the Advisory Board, the Board of Directors appointed Dr. Brian Rudman (“ Dr. Rudman Mr. Boon In connection with Dr. Rudman’s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the “ Dr. Rudman Consulting Agreement 25,000 2,000 1.00 25,000 In connection with Mr. Boon’s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the “ Mr. Boon Consulting Agreement 25,000 1.00 25,000 On January 24, 2023, we entered into Consulting Agreements with four consultants to the Company: (1) Sultan Haroon; (2) John Helfrich; (3) Justin Baker; and (4) Maja Matthews, each of whom is also an employee of Epiq Scripts. Pursuant to the Consulting Agreements, the Consultants agreed to provide us services related to the research, development, packaging and marketing for additional pharmaceutical and other over-the-counter related products during the term of the agreement, which each have a term of 18 months unless otherwise earlier terminated due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued an aggregate of 350,000 shares of common stock to the consultants as follows: (1) Sultan Haroon 150,000 shares of restricted common stock; (2) John Helfrich 25,000 shares of restricted common stock; (3) Justin Baker 25,000 shares of restricted common stock; and (4) Maja Matthews 150,000 shares of restricted common stock. The shares issued to Mr. Haroon and Ms. Matthews vest at the rate of 50,000 shares upon entry into the agreement, 50,000 shares upon the Company’s successful launch of a new product category, and 50,000 shares upon the Company’s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement. The shares issued to Mr. Helfrich and Mr. Baker vest at the rate of 10,000 shares upon entry into the agreement, 7,500 shares upon the Company’s successful launch of a new product category, and 7,500 shares upon the Company’s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement. 1.00 350,000 On March 22, 2023, the Company sold 1,250,000 4.00 5,000,000 On April 24, 2023, a warrant holder exercised private placement warrants to purchase 100,000 1.00 100,000 On April 25, 2023, a warrant holder exercised private placement warrants to purchase 100,000 1.00 100,000 On April 25, 2023, a warrant holder exercised private placement warrants to purchase 25,000 1.00 25,000 On April 25, 2023, a warrant holder exercised private placement warrants to purchase 25,000 1.00 25,000 On April 25, 2023, a warrant holder exercised private placement warrants to purchase 75,000 1.00 75,000 On April 26, 2023, a warrant holder exercised private placement warrants to purchase 100,000 1.00 100,000 On May 1, 2023, a warrant holder exercised private placement warrants to purchase 25,000 1.00 25,000 On and effective on May 1, 2023, the Company entered into an Employment Agreement with Mrs. Amanda Hammer (the “ Employment Agreement 150,000 The Employment Agreement also required the Company to grant Mrs. Hammer a sign-on bonus of (a) 75,000 restricted shares of common stock of the Company, vested in full upon issuance, and (b) options to purchase an additional 150,000 shares of common stock of the Company, under the Company’s 2022 Equity Incentive Plan (the “Plan”), with an exercise price of the greater of (i) $1.10 per share; and (ii) the closing sales price of the Company’s common stock on the Nasdaq Capital Market on the date the Employment Agreement and the grant is approved by the Board (which date was May 1, 2023), and which exercise price was $ 1.00 50,000 On May 1, 2023, we entered into a Software Development Agreement with Redlime Solutions, Inc. (“ Redlime 300,000 180,000 1.00 180,000 On May 25, 2023, the Board of Directors appointed Mr. Aaron Andrew (“ Mr. Andrew Mr. Andrew Consulting Agreement 50,000 1.10 55,000 On June 1, 2023, we entered into a Consulting Agreement with Major Dodge (“ Major 20,000 1.10 22,000 On June 1, 2023, we entered into a Production and Broadcasting Agreement with New To The Street Group, LLC (“ New To The Street 50,000 5,000 1.10 55,000 On June 5, 2023, a warrant holder exercised private placement warrants to purchase 25,000 1.00 25,000 On June 6, 2023, a warrant holder exercised private placement warrants to purchase 150,000 1.00 150,000 On June 7, 2023, a warrant holder exercised private placement warrants to purchase 75,000 1.00 75,000 On June 8, 2023, a warrant holder exercised private placement warrants to purchase 24,500 1.00 24,500 On June 21, 2023, a warrant holder exercised private placement warrants to purchase 100,000 1.00 100,000 On June 22, 2023, a warrant holder exercised private placement warrants to purchase 100,000 1.00 100,000 On June 27, 2023, a warrant holder exercised private placement warrants to purchase 100,000 1.00 100,000 On September 1, 2023, we entered into a service agreement with Greentree Financial Group, Inc. (“ Greentree Service Agreement The Company agreed to issue Greentree 75,000 40,000 (a) $20,000 on or before September 30, 2023; (b) $20,000 on or before March 31, 2024 1.13 84,750 On October 1, 2023, the Company executed a Summary of Terms and Conditions (“ Consulting Agreement Johnston 50,000 2,000 On October 10, 2023, we entered into a Consulting Agreement with Luca Consulting, LLC (“ Luca 200,000 15,000 (a) $5,000 on the signing of the agreement; (b) $5,000 on the tenth of each month throughout the remainder of the agreement. 0.63 126,000 On November 1, 2023, we entered into an Influencer Agreement with Jason Szkup (“ Scoop 10,000 30,000 0.58 17,400 On November 1, 2023, the Board of Directors appointed Dr. Douglas Christianson, ND (“ Dr. Christianson Dr. Christianson Consulting Agreement 50,000 0.58 29,000 On November 15, 2023, we renewed a Consulting Agreement with PHX Global, LLC (“ PHX 200,000 0.47 94,000 On December 11, 2023, the Company entered into a Marketing Agreement with Marius Pharmaceuticals (“ Marius Permitted Purpose Territory 100,000 Marius Shares 0.58 58,000 On December 19, 2023, the Company sold 4,000,000 0.30 1,200,000 On January 2, 2024, we entered into a Consulting Agreement with G&P General Consulting (“ G&P 250,000 500,000 0.28 70,000 500,000 On January 10, 2024, we renewed a Consulting Agreement with Luca Consulting, LLC (“ Luca 200,000 15,000 (a) $5,000 on the signing of the agreement; and (b) $5,000 on the tenth of each month throughout the remainder of the agreement. The Service Agreement includes customary indemnification obligations requiring the Company to indemnify Luca and its affiliates with regard to certain matters. 0.28 56,000 On January 11, 2024, we entered into a Consulting Agreement with First Level Capital (“ First Level 250,000 250,000 60,000 (a) $60,000 on the signing of the agreement; and (b) $60,000 on the approval by the Company. The Service Agreement includes customary indemnification obligations requiring the Company to indemnify First Level and its affiliates with regard to certain matters. 0.29 144,950 On January 18, 2024, the underwriters in the follow-on offering notified the Company that they were exercising their over-allotment option in full to purchase an additional 600,000 600,000 160,000 4,600,000 On February 7, 2024, pursuant to the Consulting Agreement with G&P, the Company issued G&P another 250,000 0.41 102,500 On March 21, 2024, we entered into Amendment to the of January 10, 2024 consulting agreement with Luca, extending the agreement for an additional six months (the “ Luca Amendment 500,000 5,000 0.1975 98,750 On March 21, 2024, we entered into a Consulting Agreement with Zvonimir Moric, an individual (“ Zee 150,000 0.1975 29,625 On April 8, 2024, the Company entered into an Equity Purchase Agreement with the Purchaser pursuant to which the Purchaser committed to purchase up to $ 25,000,000 1,000,000 0.2149 214,900 On April 25, 2024, the Company amended its Consulting Agreement with PHX dated November 7, 2023 whereby the Company agreed to issue PHX an additional 200,000 200,000 0.28 56,000 Between May 21-24, 2024, the Purchaser converted a total of 355 1,923,644 0.203 390,500 On May 21, 2024, the Company sold 250,000 0.48 119,750 On May 22, 2024, the Company sold 700,000 0.48 337,915 On May 23, 2024, we entered into a Consulting Agreement with Acorn Management Partners, L.L.C. (“ Acorn 192,308 0.52 100,000 On June 5, 2024, the Board of Directors issued 1,250,000 800,000 100,000 50,000 100,000 0.35 437,500 Options: During the year ended December 31, 2022, the Company granted a total of 1,250,000 750,000 500,000 1.10 three years On May 1, 2023, the Company granted 150,000 1.10 three years On December 28, 2023, the Company granted 1,250,000 0.32 five years On March 28, 2024, Mr. Arango resigned from his position as President and Director of the Company. As detailed in his employment agreement, 283,333 216,667 For the six months ended June 30, 2024 and 2023, $ 88,945 131,113 The following table summarizes common stock option activity: SCHEDULE OF STOCK OPTION ACTIVITY Options Weighted Average Exercise Price Outstanding, December 31, 2022 1,250,000 $ 1.10 Granted 1,400,000 $ 0.40 Exercised - - Expired - - Expired / Forfeited (283,333 ) 1.10 Outstanding, December 31, 2023 2,650,000 $ 0.73 Exercisable, December 31, 2023 1,812,500 $ 0.73 Outstanding, December 31, 2023 2,650,000 $ 0.73 Granted - $ - Exercised - - Expired / Forfeited (283,333 ) 1.10 Outstanding, June 30, 2024 2,366,667 $ 0.69 Exercisable, June 30, 2024 1,979,167 $ 0.61 The weighted average exercise prices, remaining lives for options granted, and exercisable as of June 30, 2024 were as follows: SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE Outstanding Exercisable Options Options Exercise Price Per Shares Life (Years) Weighted Average Exercise Shares Weighted Average Exercise $ 1.10 1,116,667 4.03 $ 1.10 729,167 $ 1.10 $ 0.32 1,250,000 4.50 $ 0.32 1,250,000 $ 0.32 As of June 30, 2024, the fair value of exercisable options outstanding was $ 811,261 SCHEDULE OF OPTIONS FAIR VALUE ASSUMPTIONS Fair Value of Common Stock on measurement date $ 0.99 0.29 Risk free interest rate 3.83 3.30 % Volatility 232.05 92.54 % Dividend Yield 0 % Expected Term 6.0 3.5 (1) The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date. (2) The trading volatility was determined by calculating the volatility of the Company’s peer group. (3) The Company does not expect to pay a dividend in the foreseeable future (4) The Company, in accordance with staff accounting bulletin (“ SAB Warrants: In August 2022, the Company initiated a private placement of up to $ 2 1.00 1.00 2,000,000 2,000,000 975,500 975,500 As additional consideration in connection with the IPO, upon the closing of the IPO, we granted Boustead Securities, LLC, the representative of the underwriters named in the Underwriting Agreement for the IPO, warrants to purchase 87,500 5.00 31,995 As additional consideration in connection with the follow-on offering, upon the closing of the follow-on offering, we granted Boustead Securities, LLC, the representative of the underwriters named in the Underwriting Agreement for the secondary offering, warrants to purchase 280,000 0.38 78,174 On January 22, 2024, pursuant to the Underwriting Agreement, the Company also issued a common stock purchase warrant to the representative of the underwriters for the purchase of 42,000 0.375 12,086 On April 4, 2024, pursuant to the SPA with the Purchaser, the Company issued a common stock purchase warrant for the purchase of 3,300,000 0.26 681,352 On June 28, 2024, pursuant to the SPA (as amended), the Company issued a common stock purchase warrant for the purchase of 1,000,000 0.50 260,750 On June 28 2024, pursuant to the SPA (as amended), the Company issued a common stock purchase warrant for the purchase of 500,000 1.00 122,341 As of June 30, 2024 and December 31, 2023, the fair value of warrants outstanding was $ 1,735,966 852,480 The following table summarizes common stock warrants activity: SCHEDULE OF WARRANT ACTIVITY Warrants Weighted Average Exercise Price Outstanding, December 31, 2022 2,000,000 $ 1.00 Granted 367,500 1.22 Exercised (1,024,500 ) 1.00 Expired - - Cancelled - - Outstanding, December 31, 2023 1,343,000 1.41 Exercisable, December 31, 2023 1,343,000 1.41 Outstanding, December 31, 2023 1,343,000 1.41 Granted 4,842,000 0.39 Exercised - - Expired - - Cancelled - - Outstanding, June 30, 2024 6,185,000 0.55 Exercisable, June 30, 2024 6,185,000 $ 0.55 The weighted average exercise prices, remaining lives for warrants granted, and exercisable as of June 30, 2024, were as follows: SCHEDULE OF WARRANTS OUTSTANDING AND EXERCISABLE Outstanding and Vested Warrants Weighted Average Shares Life (Years) $ 0.55 6,185,000 4.30 As of June 30, 2024, warrants to purchase 6,185,000 4.30 SCHEDULE OF WARRANTS FAIR VALUE ASSUMPTIONS Fair Value of Common Stock on measurement date $ 0.21 0.73 Risk-free interest rate From 2.95 4.38 % Volatility From 81.92 239.06 % Dividend Yield 0 % Expected Term 5 (1) The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date. (2) The trading volatility was determined by calculating the volatility of the Company’s peer group. (3) The Company does not expect to pay a dividend in the foreseeable future.	NOTE 8 – CAPITAL STOCK Preferred Stock The Company is authorized to issue up to 10,000,000 0.0001 Common Stock The Company is authorized to issue 200,000,000 0.0001 21,419,500 13,365,000 On January 3, 2023, we entered into a Consulting Agreement with DojoLabs Group, Inc. (“DojoLabs”), to provide various strategic marketing related services to the Company pursuant to a defined scope of work during the term of the agreement, which is the earlier of a) all deliverables being received by the Company pursuant to the scope of work, or b) if terminated due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company agreed to pay DojoLabs $ 100,000 50,000 1.00 100,000 On January 6, 2023, we entered into a Consulting Agreement with Bethor, Ltd. (“Bethor”), to provide strategic advisory services to the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Bethor 250,000 shares of restricted common stock with registration rights. The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $ 1.00 250,000 On January 6, 2023, the Company established an advisory board (the “Advisory Board”) and approved and adopted a charter (the “Advisory Board Charter”) to govern the Advisory Board. Pursuant to the Advisory Board Charter, the Advisory Board shall be comprised of a minimum of two (2) members, all of whom shall be appointed and subject to removal by the Board of Directors at any time. In addition to the enumerated responsibilities of the Advisory Board in the Advisory Board Charter, the primary function of the Advisory Board is to assist the Board of Directors in its general oversight of the Company’s development of new business ventures and strategic planning. In connection with the establishment of the Advisory Board, the Board of Directors appointed Dr. Brian Rudman (“Dr. Rudman”) and Mr. Jarrett Boon (“Mr. Boon”), both of whom are independent, non-Board members and non-Company employees, to the Advisory Board. Dr. Rudman will serve as Chairman of the Advisory Board. In connection with Dr. Rudman’s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the “Dr. Rudman Consulting Agreement”), dated effective January 6, 2023, with Dr. Rudman, whereby the Company agreed to issue Dr. Rudman 25,000 2,000 1.00 25,000 In connection with Mr. Boon’s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the “Mr. Boon Consulting Agreement”), dated effective January 6, 2023, with Mr. Boon, whereby the Company agreed to issue Mr. Boon 25,000 1.00 25,000 On January 24, 2023, we entered into Consulting Agreements with four consultants to the Company: (1) Sultan Haroon; (2) John Helfrich; (3) Justin Baker; and (4) Maja Matthews, each of whom is also an employee of Epiq Scripts. Pursuant to the Consulting Agreements, the Consultants agreed to provide us services related to the research, development, packaging and marketing for additional pharmaceutical and other over-the-counter related products during the term of the agreement, which each have a term of 18 months unless otherwise earlier terminated due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued an aggregate of 350,000 shares of common stock to the consultants as follows: (1) Sultan Haroon 150,000 shares of restricted common stock; (2) John Helfrich 25,000 shares of restricted common stock; (3) Justin Baker 25,000 shares of restricted common stock; and (4) Maja Matthews 150,000 shares of restricted common stock. The shares issued to Haroon and Matthews vest at the rate of 50,000 shares upon entry into the agreement, 50,000 shares upon the Company’s successful launch of a new product category, and 50,000 shares upon the Company’s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement. The shares issued to Helfrich and Baker vest at the rate of 10,000 shares upon entry into the agreement, 7,500 shares upon the Company’s successful launch of a new product category, and 7,500 shares upon the Company’s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement. Any shares not vested by the eighteen-month anniversary of the applicable agreement are forfeited. The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $ 1.00 350,000 On March 22, 2023, the Company sold 1,250,000 4.00 5,000,000 On April 24, 2023, a warrant holder exercised private placement Warrants to purchase 100,000 1.00 100,000 On April 25, 2023, a warrant holder exercised private placement Warrants to purchase 100,000 1.00 100,000 On April 25, 2023, a warrant holder exercised private placement Warrants to purchase 25,000 1.00 25,000 On April 25, 2023, a warrant holder exercised private placement Warrants to purchase 25,000 1.00 25,000 On April 25, 2023, a warrant holder exercised private placement Warrants to purchase 75,000 1.00 75,000 On April 26, 2023, a warrant holder exercised private placement Warrants to purchase 100,000 1.00 100,000 On May 1, 2023, a warrant holder exercised private placement Warrants to purchase 25,000 1.00 25,000 On and effective on May 1, 2023, the Company entered into an Employment Agreement with Mrs. Amanda Hammer (the “Employment Agreement”). The Employment Agreement provides for Mrs. Hammer to serve as Chief Operating Officer of the Company for an initial three-year term extending through May 1, 2026, provided that the agreement automatically renews for additional one-year terms thereafter in the event neither party provides the other at least 60 days prior notice of their intention not to renew the terms of the agreement. The agreement provides for Mrs. Hammer to receive an annual salary of $ 150,000 1.00 50,000 On May 1, 2023, we entered into a Software Development Agreement with Redlime Solutions, Inc. (“Redlime”) to provide software development services during the term of the agreement, which is for twelve months. In consideration for agreeing to provide the services under the agreement, the Company agreed to pay Redlime $ 300,000 180,000 1.00 180,000 On May 25, 2023, the Board of Directors appointed Mr. Aaron Andrew (“Mr. Andrew”), an independent, non-Board member and non-Company employee, to the Advisory Board. In connection with Mr. Andrew’s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the “Mr. Andrew Consulting Agreement”), dated effective May 25, 2023, with Mr. Andrew, whereby the Company agreed to issue Mr. Andrew 50,000 1.10 55,000 On June 1, 2023, we entered into a Consulting Agreement with Major Dodge (“Major”), to provide acting and production related services to the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Major 20,000 1.10 22,000 On June 1, 2023, we entered into a Production and Broadcasting Agreement with New To The Street Group, LLC (“New To The Street”), to provide production, broadcasting and other marketing related services to the Company during the term of the agreement, which is for 3 months unless otherwise earlier terminated. In consideration for agreeing to provide the services under the agreement, the Company issued New To The Street 50,000 5,000 1.10 55,000 On June 5, 2023, a warrant holder exercised private placement Warrants to purchase 25,000 1.00 25,000 On June 6, 2023, a warrant holder exercised private placement Warrants to purchase 150,000 1.00 150,000 On June 7, 2023, a warrant holder exercised private placement Warrants to purchase 75,000 1.00 75,000 On June 8, 2023, a warrant holder exercised private placement Warrants to purchase 24,500 1.00 24,500 On June 21, 2023, a warrant holder exercised private placement Warrants to purchase 100,000 1.00 100,000 On June 22, 2023, a warrant holder exercised private placement Warrants to purchase 100,000 shares of common stock with an exercise price of $ 1.00 per share in consideration for $ 100,000 in cash. The shares of common stock issuable upon exercise of the warrants were registered under the Securities Act. On June 27, 2023, a warrant holder exercised private placement Warrants to purchase 100,000 1.00 100,000 On September 1, 2023, we entered into a service agreement with Greentree Financial Group, Inc. (“Greentree” and the “Service Agreement”). Pursuant to the Service Agreement, Greentree agreed to perform the following services: (a) bookkeeping services for the Company for the period from October 1, 2023 through September 30, 2024; (b) advice and assistance to the Company in connection with the conversion of its financial reporting systems, including its projected financial statements, to a format that is consistent with US GAAP; (c) assistance to the Company with compliance filings for the quarters ended September 30, 2023, March 31, 2024, June 30, 2024 and the year ended December 31, 2023, including the structure and entries as well as assistance with US GAAP footnotes; (d) reviewing, and providing advice to the Company on, all documents and accounting systems relating to its finances and transactions, with the purpose of bringing such documents and systems into compliance with US GAAP or disclosures required by the SEC; and (e) providing necessary consulting services and support as a liaison for the Company to third party service providers, including coordination amongst the Company and its attorneys, CPAs and transfer agent. Since February 2015, Mr. Eugene (Gene) M. Johnston, our Chief Financial Officer (who was appointed October 1, 2022) has served as an Audit Manager for Greentree. The Company agreed to issue Greentree 75,000 40,000 (a) $20,000 on or before September 30, 2023; (b) $20,000 on or before March 31, 2024. 1.13 84,750 On October 1, 2023, the Company executed a Summary of Terms and Conditions (“Consulting Agreement”) with Gene Johnston (“Johnston”) continuing his appointment as the Company’s Chief Financial Officer on a full-time basis for a term of 12 months. Pursuant to the Consulting Agreement, the Company issued Johnston 50,000 2,000 On October 10, 2023, we entered into a Consulting Agreement with Luca Consulting, LLC (“Luca”), to provide certain management and consulting services to the Company during the term of the agreement, which is for three months unless otherwise earlier terminated due to breach of the agreement by either party. In consideration for agreeing to provide the services under the agreement, the Company issued 200,000 15,000 (a) $5,000 on the signing of the agreement; (b) $5,000 on the tenth of each month throughout the remainder of the agreement. 0.63 126,000 On November 1, 2023, we entered into an Influencer Agreement with Jason Szkup (“Scoop”) to promote its products or services through social media platforms and other online channels, In consideration for agreeing to provide the services under the agreement, the Company agreed to pay Scoop $ 10,000 30,000 0.58 17,400 On November 1, 2023, the Board of Directors appointed Dr. Douglas Christianson, ND (“Dr. Christianson”), an independent, non-Board member and non-Company employee, to the Advisory Board. In connection with Dr. Christianson’s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the “Dr. Christianson Consulting Agreement”), with Dr. Christianson, whereby the Company agreed to issue Dr. Christianson 50,000 0.58 29,000 On November 15, 2023, we renewed a Consulting Agreement with PHX Global, LLC (“PHX”), which is owned by Peter “Casey” Jensen, who is a member of the Board of Directors of American International. Pursuant to the Consulting Agreement, PHX agreed to provide consulting and general business advisory services as reasonably requested by the Company during the term of the agreement, which was for 12 months, unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued PHX 200,000 0.47 94,000 On December 11, 2023, the Company entered into a Marketing Agreement with Marius Pharmaceuticals (“Marius”) to market and sell KYZATREX®, an innovative FDA-approved oral Testosterone Replacement Therapy (TRT) product, under the program, ‘PRIME’ by MangoRx. During the Term, Marius grants to MangoRx a non-exclusive, non-transferable, royalty-free license to use the Marius Marks in the United States (the “Territory”) for the sole purpose of the Permitted Purpose. The term of the initial agreement is for two years, automatically renewable for successive one year terms, subject to certain performance targets as agreed upon each year. As consideration for the license granted herein, MangoRx shall issue to Marius one hundred thousand ( 100,000 0.58 58,000 On December 19, 2023 the Company sold 4,000,000 0.30 1,200,000 Options: During the year ended December 31, 2022, the Company granted a total of 1,250,000 750,000 500,000 1.10 three years On May 1, 2023, the Company granted 150,000 1.10 three years On December 28, 2023, the Company granted 1,250,000 0.32 five years As of December 31, 2023 and 2022, $ 624,463 82,267 The following table summarizes common stock options activity: The following table summarizes common stock options activity: SCHEDULE OF STOCK OPTION ACTIVITY Options Weighted Average Exercise Price December 31, 2021 - $ - Granted 1,250,000 1.10 Exercised - - Expired - - Outstanding, December 31, 2022 1,250,000 $ 1.10 Exercisable, December 31, 2022 133,333 $ 1.10 Outstanding, December 31, 2023 1,250,000 $ 1.10 Granted 1,400,000 $ 0.40 Exercised - - Expired - - Outstanding, December 31, 2023 2,650,000 $ 0.73 Exercisable, December 31, 2023 1,812,500 $ 0.73 The weighted average exercise prices, remaining lives for options granted, and exercisable as of December 31, 2023 were as follows: Outstanding Options Exercisable Options Options Exercise Price Per Share Shares Life (Years) Weighted Average Exercise Price Shares Weighted Average Exercise Price $ 1.10 1,400,000 4.28 $ 1.10 562,500 $ 1.10 $ 0.32 1,250,000 5.00 $ 0.32 1,250,000 $ 0.32 As of December 31, 2023, the fair value of options outstanding was $ 573,202 SCHEDULE OF FAIR VALUE ASSUMPTIONS Fair Value of Common Stock on measurement date $ 1.00 0.32 Risk free interest rate 3.83 3.30 % Volatility 232.05 92.54 % Dividend Yield 0 % Expected Term 6.0 3.5 (1) The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date. (2) The trading volatility was determined by calculating the volatility of the Company’s peer group. (3) The Company does not expect to pay a dividend in the foreseeable future (4) The Company, in accordance with staff accounting bulletin (“SAB”)14-D.2, used the simplified method (plain vanilla) to determine the overall expected term Warrants: As additional consideration in connection with the IPO, upon the closing of the IPO, we granted Boustead Securities, LLC, the representative of the underwriters named in the Underwriting Agreement for the IPO, warrants to purchase 87,500 5.00 31,995 As additional consideration in connection with the follow on offering, upon the closing of the follow on offering, we granted Boustead Securities, LLC, the representative of the underwriters named in the Underwriting Agreement for the secondary offering, warrants to purchase 280,000 0.38 271,216 As of December 31, 2023 and 2022, the fair value of warrants outstanding to investors was $ 852,480 581,264 The following table summarizes common stock warrants activity: SCHEDULE OF WARRANT ACTIVITY Warrants Weighted Average Exercise Price Outstanding, December 31, 2021 - $ - Granted 2,210,070 1.00 Exercised - - Expired - - Cancelled (210,070 ) 1.00 Outstanding, December 31, 2022 2,000,000 1.00 Exercisable, December 31, 2022 2,000,000 $ 1.00 Granted 367,500 1.22 Exercised (1,024,500 ) 1.00 Expired - - Cancelled - - Outstanding, December 31, 2023 1,343,000 1.43 Exercisable, December 31, 2023 1,343,000 $ 1.43 The weighted average exercise prices, remaining lives for warrants granted, and exercisable as of December 31, 2023, were as follows: Outstanding and Vested Warrants Weighted Average Warrant Exercise Price Per Share Shares Life (Years) $ 1.43 1,343,000 2.07 As of December 31, 2023, warrants to purchase 1,063,000 3.83 SCHEDULE OF FAIR VALUE ASSUMPTIONS Fair Value of Common Stock on measurement date $ 0.37 0.97 Risk-free interest rate From 2.95 4.00 % Volatility From 81.92 169.22 % Dividend Yield 0 % Expected Term 5 (1) The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date. (2) The trading volatility was determined by calculating the volatility of the Company’s peer group. (3) The Company does not expect to pay a dividend in the foreseeable future.

GOING CONCERN

GOING CONCERN	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 10 – GOING CONCERN These condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the discharge of liabilities in the normal course of business for the foreseeable future. As reflected in the accompanying condensed consolidated financials, the Company had a net loss of $ 4,758,936 15,986,733	NOTE 9 – GOING CONCERN These financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the discharge of liabilities in the normal course of business for the foreseeable future. As reflected in the accompanying financials, the Company had a net loss of $ 9,212,417 11,228,173

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 11 – COMMITMENTS AND CONTINGENCIES In the ordinary course of business, the Company may become a party to lawsuits involving various matters. The impact and outcome of litigation, if any, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm its business. The Company is not currently subject to any such litigation. Operating Leases The Company has a lease for an office in Dallas, Texas classified as operating leases under ASC 842. On September 28, 2022, and with an effective date of October 1, 2022, the Company entered into a Lease Agreement with Rox Trep Tollway, L.P. (the “ Landlord Lease Agreement The Lease Agreement has a term of thirty-eight ( 38 5,777.63 Base Rent 2.45 Proportionate Rent 16,942 The Company utilizes the incremental borrowing rate in determining the present value of lease payments unless the implicit rate is readily determinable. The Company used an estimated incremental borrowing rate of 8 The Company has right-of-use assets of $ 90,011 97,545 16,492 0 SCHEDULE OF MATURITY OF LEASE LIABILITIES Maturity of Lease Liabilities at June 30, 2024 Amount 2024 $ 35,950 2025 67,589 Total lease payments 103,539 Less: Imputed interest (5,994 ) Present value of lease liabilities $ 97,545	NOTE 10 – COMMITMENTS AND CONTINGENCIES In the ordinary course of business, the Company may become a party to lawsuits involving various matters. The impact and outcome of litigation, if any, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm its business. The Company is not currently subject to any such litigation. Operating Leases The Company has a lease for an office in Dallas, Texas classified as operating leases under ASC 842. On September 28, 2022, and with an effective date of October 1, 2022, the Company entered into a Lease Agreement with Rox Trep Tollway, L.P. (the “Landlord”) to lease and occupy approximately 2,201 Lease Agreement 38 5,777.63 Base Rent 2.45 Proportionate Rent 16,942 The Company utilizes the incremental borrowing rate in determining the present value of lease payments unless the implicit rate is readily determinable. The Company used an estimated incremental borrowing rate of 8 The Company has right-of-use assets of $ 119,262 and operating lease liabilities of $ 128,679 as of December 31, 2023. Operating lease expense for the year ended December 31, 2023 was $ 65,274 . The Company has recorded $ 0 in impairment charges related to right-of-use assets during the year ended December 31, 2023. SCHEDULE OF MATURITY OF LEASE LIABILITIES Maturity of Lease Liabilities at December 31, 2023 Amount 2024 $ 71,716 2025 67,589 Later years - Total lease payments 139,305 Less: Imputed interest (10,626 ) Present value of lease liabilities $ 128,679

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 11 - INCOME TAXES On December 22, 2017, the U.S. enacted the Tax Cuts and Jobs Act (the “Act”), which significantly changed U.S. tax law. The Act lowered the Company’s U.S. statutory federal income tax rate from 35 21 The Act also created a new minimum tax on certain future foreign earnings. The impact of the Act increased the Company’s deferred tax asset related to the Company’s net operating loss by approximately $ 9,212,417 9,212,417 We record tax positions as liabilities in accordance with ASC 740 and adjust these liabilities when our judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from our current estimate of the recognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. As of December 31, 2023, and 2022 we have not recorded any uncertain tax positions in our financial statements. The effective US Federal Income Corporate Tax Rates for 2023 and 2022 are 21 21 The Company has net operating loss carryforwards of approximately $ 11,228,173 The Company has a deferred tax asset as shown in the following: SCHEDULE OF DEFERRED TAX ASSET Year Ending December 31, 2023 Year Ending December 31, 2022 Deferred Tax Asset 11,228,173 2,015,756 Valuation Allowance (11,228,173 ) (2,015,756 ) Net Deferred Tax Asset $ — $ —

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 12 – SUBSEQUENT EVENTS The Company evaluates events that have occurred after the condensed consolidated balance sheet date but before the condensed consolidated financial statements are issued. Based on the evaluation, the Company identified the following subsequent events: On July 8, 2024, 135 148,500 536,682 0.2767 On July 9, 2024, the Company entered into a Master Distribution Agreement with ISFLST, Inc. (“ ISFLST Distribution Agreement Products Pursuant to the Distribution Agreement, ISFLST agreed to use commercially reasonable efforts to sell and promote the sale of the Products in Asia Pacific and Latin America (excluding Mexico), and we provided ISFLST a non-exclusive, non-transferable license to market and sell the Products, and grant sub-licenses (subject to certain pre-requisites and limitations described in greater detail in the Distribution Agreement) to sell the Products, in the Market. We also agreed, subject to certain future mutually agreed milestones that ISFLST could earn exclusive rights to market the Products in the applicable “ Market The Distribution Agreement has a term of three years and is automatically renewable thereafter for three additional one year terms, unless either party provides the other notice of non-renewal at least 90 days prior to an automatic renewal date. The agreement may also be terminated by the non-breaching party upon the material breach of the agreement by the counterparty and failure to cure such breach after 90 days written notice, or upon insolvency. The Distribution Agreement includes customary confidentiality requirements of the parties, representations and warranties of the parties, mutual indemnification rights, disclaimers of warranties and limitation of liabilities, and force majeure provisions The Distribution Agreement also includes a non-solicitation obligation of ISFLST, which applies during the term of the agreement and for two years thereafter. All pricing information will be mutually agreed to by the parties and set forth in a separate purchase order, subject to availability and volume requirements. On July 25, 2024, 10 11,000 33,670 0.3267 On July 30, 2024, we entered into a Consulting Agreement with John Dorsey, an individual (“Dorsey”). Pursuant to the consulting agreement, Dorsey agreed to provide certain marketing and general related services as it relates expanding the sales of the Company’s products and additional services as reasonably requested by the Company during the Term of the Agreement, which is for 12 months, unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company agreed to pay Dorsey $6,000 a month and issued Dorsey a total of 200,000 shares, which vest in accordance with the following vesting schedule; a) 50,000 shares vest upon the execution of the Agreement, b) 75,000 shares vest upon the three (3) month anniversary of the Agreement, and c) 75,000 shares vest upon the six (6) month anniversary of the Agreement (the “Dorsey Consulting Shares”). 0.4209 84,180 The Company further agreed to issue Dorsey an additional 200,000	NOTE 12 – SUBSEQUENT EVENTS On January 2, 2024, we entered into a Consulting Agreement with G&P General Consulting (“G&P”), Pursuant to the Consulting Agreement, G&P agreed to provide consulting and general business advisory services as it relates to the expansion of the Company’s products into additional international territory’s, including, but not limited to, the United Arab Emirates (UAE), China, Japan, Korea, and in certain regions of Asia and additional services as reasonably requested by the Company during the Term of this Agreement as reasonably requested by the Company during the term of the agreement, which was for 12 months, unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued G&P 250,000 500,000 0.28 70,000 On January 10, 2024, we renewed a Consulting Agreement with Luca Consulting, LLC (“Luca”), to provide certain management and consulting services to the Company during the term of the agreement, which is for three months unless otherwise earlier terminated due to breach of the agreement by either party. In consideration for agreeing to provide the services under the agreement, the Company issued 200,000 15,000 (a) $5,000 on the signing of the agreement; (b) $5,000 on the tenth of each month throughout the remainder of the agreement. The Service Agreement includes customary indemnification obligations requiring the Company to indemnify Luca and its affiliates with regard to certain matters. 0.28 56,000 On January 11, 2024, we entered into a Consulting Agreement with First Level Capital (“First Level”), to provide certain management and consulting services to the Company during the term of the agreement, which is for six months unless otherwise earlier terminated due to breach of the agreement by either party. In consideration for agreeing to provide the services under the agreement, the Company issued an initial 250,000 250,000 60,000 (a) $60,000 on the signing of the agreement; (b) $60,000 on the approval by the Company. The Service Agreement includes customary indemnification obligations requiring the Company to indemnify First Level and its affiliates with regard to certain matters. 0.28 70,000 On January 18, 2024, the Underwriters in the follow-on offering notified the Company that they were exercising their over-allotment option in full to purchase an additional 600,000 600,000 160,000 4,600,000 On January 22, 2024, pursuant to the Underwriting Agreement, the Company also issued a common stock purchase warrant to the Representative for the purchase of 42,000 0.375 Warrant On March 21, 2024, we entered into Amendment to the of January 10, 2024 consulting agreement with Luca extending the agreement for an additional 6 months (the “Luca Amendment”). In consideration for entering into the Luca Amendment, the Company issued 500,000 5,000 0.1975 98,750 On March 21, 2024, we entered into a Consulting Agreement with Zvonimir Moric (the “Zee”). Pursuant to the consulting agreement, Zee agreed to provide consulting and general business advisory services as it relates to making introductions to strategic partners to expand the sales of the Company’s products and additional services as reasonably requested by the Company during the Term of this Agreement as reasonably requested by the Company during the term of the agreement, which is for 12 months, unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Zee 150,000 0.1975 29,625 On March 1, 2024, the Company borrowed $ 37,500 On March 18, 2024, the Company borrowed $ 50,000 On March 25, 2024, at a Special Meeting of the stockholders of the Company, the stockholders of the Company approved a First Amendment to the Mangoceuticals, Inc. 2022 Equity Incentive Plan (“ First Amendment 2022 Plan The First Amendment increased the number of shares of common stock available for awards under the Incentive Plan, such that currently, subject to adjustment in connection with the payment of a stock dividend, a stock split or subdivision or combination of the shares of common stock, or a reorganization or reclassification of the Company’s common stock, the aggregate number of shares of common stock which may be issued pursuant to awards under the 2022 Plan is currently the sum of (i) 10,000,000 2,000,000 26,000,000 26,000,000 Also at the Special Meeting, the stockholders approved an amendment to the Company’s Second Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Company’s issued and outstanding shares of our common stock, par value $ 0.0001

DEPOSITS

DEPOSITS	6 Months Ended
	Jun. 30, 2024
Schedule Of Warrants Outstanding And Exercisable
DEPOSITS	NOTE 4 – DEPOSITS Additionally, the Company signed a lease agreement for office space, effective October 1, 2022, which included an initial security deposit of $ 16,942 16,942

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation US GAAP	Basis of Presentation
Cash Equivalents	Cash Equivalents Highly liquid investments with original maturities of three months or less are considered cash equivalents. The Company maintains the majority of its cash accounts at a commercial bank. The Federal Deposit Insurance Corporation (“ FDIC 250,000 no	Cash Equivalents Highly liquid investments with original maturities of three months or less are considered cash equivalents. The Company maintains the majority of its cash accounts at a commercial bank. The Federal Deposit Insurance Corporation (“FDIC”) insures the total cash balance up to $ 250,000 no
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with ASC 740, Accounting for Income Taxes, as clarified by ASC 740-10, Accounting for Uncertainty in Income Taxes. Under this method, deferred income taxes are determined based on the estimated future tax effects of differences between the financial statement and tax basis of assets and liabilities given the provisions of enacted tax laws. Deferred income tax provisions and benefits are based on changes to the assets or liabilities from year to year. In providing for deferred taxes, the Company considers tax regulations of the jurisdictions in which the Company operates, estimates of future taxable income, and available tax planning strategies. If tax regulations, operating results or the ability to implement tax-planning strategies vary, adjustments to the carrying value of deferred tax assets and liabilities may be required. Valuation allowances are recorded related to deferred tax assets based on the “more likely than not” criteria of ASC 740. ASC 740-10 requires that the Company recognize the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the “more-likely-than-not” threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.	Income Taxes The Company is a taxable entity and recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Income taxes are provided in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740, Income Taxes
Net Loss Per Common Share	Net Loss Per Common Share We compute net loss per share in accordance with ASC 260, Earning per Share EPS 2,366,667 6,185,000 no 2,650,000 1,343,000 no	Net Loss Per Common Share We compute net loss per share in accordance with ASC 260, Earning per Share 2,650,000 1,343,000 1,250,000 2,000,000
Use of Estimates and Assumptions	Use of Estimates and Assumptions The preparation of financial statements in accordance with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results can, and in many cases will, differ from those estimates.	Use of Estimates and Assumptions The preparation of financial statements in accordance with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results can, and in many cases will, differ from those estimates.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with FASB ASC 820, Fair Value Measurement ASC 820 Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The following tables summarize our financial instruments measured at fair value as of June 30, 2024 and December 31, 2023. SCHEDULE OF FINANCIAL INSTRUMENTS MEASUREMENT AT FAIR VALUE Level 1 Level 2 Level 3 Fair Value Measurements at June 30, 2024 Level 1 Level 2 Level 3 Assets Cash $ 490,243 $ - $ - Total assets 490,243 - - Liabilities Total liabilities - - - Fair value, net asset (liability) $ 490,243 $ - $ - Level 1 Level 2 Level 3 Fair Value Measurements at December 31, 2023 Level 1 Level 2 Level 3 Assets Cash $ 739,006 $ - $ - Total assets 739,006 - - Liabilities Total liabilities - - - Fair value, net asset (liability) $ 739,006 $ - $ -	Fair Value of Financial Instruments The Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with FASB ASC 820, Fair Value Measurement Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one more significant inputs or significant value drivers are unobservable. The following tables summarize our financial instruments measured at fair value as of December 31, 2023 and 2022. SCHEDULE OF FINANCIAL INSTRUMENTS MEASUREMENT AT FAIR VALUE Level 1 Level 2 Level 3 Fair Value Measurements at December 31, 2023 Level 1 Level 2 Level 3 Assets Cash $ 739,006 $ - $ - Total assets 739,006 - - Liabilities Total liabilities - - - Fair value, net asset (liability) $ 739,006 $ - $ - Level 1 Level 2 Level 3 Fair Value Measurements at December 31, 2022 Level 1 Level 2 Level 3 Assets Cash $ 682,860 $ - $ - Total assets 682,860 - - Liabilities Total liabilities - - - Fair value, net asset (liability) $ 682,860 $ - $ -
Property and Equipment	Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from the disposition is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of three ( 3 5	Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from the disposition is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of three ( 3 5
Concentration and Risks	Concentration and Risks The Company’s operations are subject to risks including financial, operational, regulatory and other risks including the potential risk of business failure. For the six months ended June 30, 2024 and 2023, the Company had no significant revenue from continuing operations which were derived from a single or a few major customers.	Concentration and Risks The Company’s operations are subject to risks including financial, operational, regulatory and other risks including the potential risk of business failure. For the years ended December 31, 2023 and 2022, the Company had no significant revenue from continuing operations which were derived from a single or a few major customers.
Black-Scholes Option Pricing Model	Black-Scholes Option Pricing Model The Company uses a Black-Scholes option pricing model to determine the fair value of warrants and options issued.	Black-Scholes Option Pricing Model The Company uses a Black-Scholes option pricing model to determine the fair value of warrants and options issued.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the effect of recently issued standards that are not yet effective will not have a material effect on its financial position or results of operations upon adoption. In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures (Topic 280). This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”) and included within each reported measure of a segment’s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment’s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is also permitted. This ASU will likely result in us including the additional required disclosures when adopted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending December 31, 2024. In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is also permitted for annual financial statements that have not yet been issued or made available for issuance. This ASU will result in the required additional disclosures being included in our consolidated financial statements, once adopted.	Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the effect of recently issued standards that are not yet effective will not have a material effect on its financial position or results of operations upon adoption. In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40) ASU 2020-06
Related Parties	Related Parties The Company follows subtopic 850-10 of FASB ASC 850, Related Party Pursuant to Section 850-10-20, the related parties include a. affiliates of the Company; b. Entities for which investments in their equity securities would be required, absent the election of the fair value option under the guidance of Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company; f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g. other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests. The consolidated financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of financial statements is not required in those statements. The disclosures shall include: a. the nature of the relationship(s) involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement. Material related party transactions have been identified in Notes 3, 7 and 9 in the notes to consolidated financial statements.	Related Parties The Company follows subtopic 850-10 of FASB ASC 850, Related Party Disclosures for the identification of related parties and disclosure of related party transactions. Pursuant to Section 850-10-20, the related parties include a. affiliates of the Company; b. Entities for which investments in their equity securities would be required, absent the election of the fair value option under the guidance of Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company; f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g. other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests. The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of financial statements is not required in those statements. The disclosures shall include: a. the nature of the relationship(s) involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement. Material related party transactions have been identified in Notes 3, 6 and 8 in the notes to financial statements.
Stock-Based Compensation	Stock-Based Compensation The Company recognizes compensation costs to employees under FASB ASC 718 Compensation - Stock Compensation ASC 718	Stock-Based Compensation The Company recognizes compensation costs to employees under FASB ASC 718 Compensation - Stock Compensation (“ASC 718”). Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include stock options and warrants. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option and warrant grant.
Revenue Recognition	Revenue Recognition The Company follows the provisions of ASC 606. Revenue from Contracts with Customer for recording and recognizing revenue from customers The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services and has met its performance obligation. For revenue generated through its online platform, the Company defines its customer as an individual who purchases products or services through websites. The transaction price in the Company’s contracts with customers is the total amount of consideration to which the Company expects to be entitled in exchange for transferring products or services to the customer. The Company’s contracts that contain prescription products issued as the result of a consultation include two performance obligations: access to (i) products and (ii) consultation services. The Company’s contracts for prescription refills have a single performance obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised product to the customer and, in contracts that contain services, by the provision of consultation services to the customer. The Company satisfies its performance obligation for products at a point in time, which is upon delivery of the products to a third-party carrier. The Company satisfies its performance obligation for services over the period of the consultation service, which is typically a few days. The customer obtains control of the products and services upon the Company’s completion of its performance obligations. The Company has entered into a Physician Services Agreement with BrighterMD, LLC dba Doctegrity (“ Doctegrity Additionally, the Company has entered into a Master Services Agreement and Statement of Work with Epiq Scripts, LLC (“ Contracted Pharmacy The Company accounts for shipping activities, consisting of direct costs to ship products performed after the control of a product has been transferred to the customer, in cost of revenue.	Revenue Recognition The Company follows the provisions of ASC 606. Revenue from Contracts with Customer for recording and recognizing revenue from customers The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services and has met its performance obligation. For revenue generated through its online platform, the Company defines its customer as an individual who purchases products or services through websites. The transaction price in the Company’s contracts with customers is the total amount of consideration to which the Company expects to be entitled in exchange for transferring products or services to the customer. The Company’s contracts that contain prescription products issued as the result of a consultation include two performance obligations: access to (i) products and (ii) consultation services. The Company’s contracts for prescription refills have a single performance obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised product to the customer and, in contracts that contain services, by the provision of consultation services to the customer. The Company satisfies its performance obligation for products at a point in time, which is upon delivery of the products to a third-party carrier. The Company satisfies its performance obligation for services over the period of the consultation service, which is typically a few days. The customer obtains control of the products and services upon the Company’s completion of its performance obligations. The Company has entered into a Physician Services Agreement with BrighterMD, LLC dba Doctegrity (“Doctegrity”) to provide online telemedicine technology services to the Company. The Company accounts for service revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company determines which providers provide the consultation to the customer; (ii) the Company is primarily responsible for the satisfactory fulfillment and acceptability of the services; (iii) the Company incurs costs for consultation services even for visits that do not result in a prescription and the sale of products; and (iv) the Company, at its sole discretion, sets all listed prices charged on its websites for products and services. Additionally, the Company has entered into a Master Services Agreement and Statement of Work with Epiq Scripts, LLC (“Contracted Pharmacy”), which is a related party, to provide pharmacy and compounding services to the Company to fulfill its promise to customers for contracts that include sale of prescription products and to fill prescriptions that are ordered by the Company’s customers for fulfillment through the Company’s websites. The Company accounts for prescription product revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company has sole discretion in determining which Contracted Pharmacy fills a customer’s prescription; (ii) Contracted Pharmacy fills the prescription based on fulfillment instructions provided by the Company, including using the Company’s branded packaging for generic products; (iii) the Company is primarily responsible to the customer for the satisfactory fulfillment and acceptability of the order, and; (iv) the Company, at its sole discretion, sets all listed prices charged on its websites for products and services. The Company accounts for shipping activities, consisting of direct costs to ship products performed after the control of a product has been transferred to the customer, in cost of revenue.
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value with cost being determined on a first-in, first-out (“ FIFO no	Inventories Inventories are stated at the lower of cost or net realizable value with cost being determined on a first-in, first-out (“FIFO”) basis. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. During the years ended December 31, 2023 and 2022, there were no
Marketing and Advertising	Marketing and Advertising The Company follows the policy of charging the costs of marketing and advertising to expense as incurred. The Company charged $ 1,081,627 912,997	Marketing and Advertising The Company follows the policy of charging the costs of marketing and advertising to expense as incurred. The Company charged $ 2,097,505 352,860
Subsequent Events	Subsequent Events The Company follows the guidance in Section 855-10-50 of FASB ASC 855, Subsequent Events	Subsequent Events The Company follows the guidance in Section 855-10-50 of FASB ASC 855, Subsequent Events
Reclassifications	Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of Mangoceuticals, Inc. and all wholly and majority-owned subsidiaries. All significant intercompany transactions and balances between the Company and its subsidiaries are eliminated upon consolidation. Wholly-owned subsidiaries: MangoRx UK Limited MangoRx IP Holdings, LLC Majority-owned subsidiaries: The Company owns 98
Non-Controlling Interest	Non-Controlling Interest The Company owns 98
Segment Reporting	Segment Reporting The Company operates as one segment, in which management uses one measure of profitability, and all of the Company’s assets are located in the United States of America. The Company does not operate separate lines of business or separate business entities with respect to any of its product candidates. Accordingly, the Company does not have separately reportable segments.
Intangible Assets	Intangible Assets Intangible assets that have indefinite useful life are patents as of June 30,2024. The Company evaluates indefinite-lived intangible assets each reporting period to determine whether events and circumstances continue to support indefinite useful lives. The value of indefinite-lived intangible assets is not amortized, but tested for impairment annually or whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. As such, no
Foreign Currency Translation and transaction	Foreign Currency Translation and transaction The Company’s principal country of operations is United States. The financial position and results of its operations are determined using U.S. Dollars (“US$”), the local currency, as the functional currency. The Company’s financial statements are reported using the U.S. Dollars (“US$” or “$”). The results of operations and the statements of cash flows denominated in foreign currency are translated at the average rate of exchange during the reporting period. Assets and liabilities denominated in foreign currencies at the balance sheet date are translated at the applicable rates of exchange in effect at that date. The equity denominated in the functional currency is translated at the historical rate of exchange at the time of capital contribution. Because cash flows are translated based on the average translation rate, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheets. Translation adjustments arising from the use of different exchange rates from period to period are included as a separate component of accumulated other comprehensive income (loss) included in statements of changes in shareholders’ equity. Gains and losses from foreign currency transactions are included in the Company’s statements of operations and comprehensive income (loss). The following table outlines the currency exchange rates that were used in preparing the financial statements: SCHEDULE OF FOREIGN CURRENCY TRANSLATION AND TRANSACTION June 30, June 30, 2024 2023 Period-end spot rate US$ 1 0.54 N/A Average rate US$ 1 0.58 N/A

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
SCHEDULE OF FINANCIAL INSTRUMENTS MEASUREMENT AT FAIR VALUE	The following tables summarize our financial instruments measured at fair value as of June 30, 2024 and December 31, 2023. SCHEDULE OF FINANCIAL INSTRUMENTS MEASUREMENT AT FAIR VALUE Level 1 Level 2 Level 3 Fair Value Measurements at June 30, 2024 Level 1 Level 2 Level 3 Assets Cash $ 490,243 $ - $ - Total assets 490,243 - - Liabilities Total liabilities - - - Fair value, net asset (liability) $ 490,243 $ - $ - Level 1 Level 2 Level 3 Fair Value Measurements at December 31, 2023 Level 1 Level 2 Level 3 Assets Cash $ 739,006 $ - $ - Total assets 739,006 - - Liabilities Total liabilities - - - Fair value, net asset (liability) $ 739,006 $ - $ -	SCHEDULE OF FINANCIAL INSTRUMENTS MEASUREMENT AT FAIR VALUE Level 1 Level 2 Level 3 Fair Value Measurements at December 31, 2023 Level 1 Level 2 Level 3 Assets Cash $ 739,006 $ - $ - Total assets 739,006 - - Liabilities Total liabilities - - - Fair value, net asset (liability) $ 739,006 $ - $ - Level 1 Level 2 Level 3 Fair Value Measurements at December 31, 2022 Level 1 Level 2 Level 3 Assets Cash $ 682,860 $ - $ - Total assets 682,860 - - Liabilities Total liabilities - - - Fair value, net asset (liability) $ 682,860 $ - $ -
SCHEDULE OF FOREIGN CURRENCY TRANSLATION AND TRANSACTION	The following table outlines the currency exchange rates that were used in preparing the financial statements: SCHEDULE OF FOREIGN CURRENCY TRANSLATION AND TRANSACTION June 30, June 30, 2024 2023 Period-end spot rate US$ 1 0.54 N/A Average rate US$ 1 0.58 N/A

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY PLANT AND EQUIPMENT	SCHEDULE OF PROPERTY PLANT AND EQUIPMENT June 30, 2024 December 31, 2023 Computers 5,062 5,062 Equipment 119,819 119,819 Less accumulated depreciation: (1,749 ) (28,752 ) Disposed equipment (119,819 ) 119,819 Property and equipment, net 3,313 96,129	SCHEDULE OF PROPERTY PLANT AND EQUIPMENT December 31, 2023 December 31, 2022 Computers 5,062 5,062 Equipment 119,819 116,300 Less accumulated depreciation: (28,752 ) (3,863 ) Property and equipment, net 96,129 117,499

CAPITAL STOCK (Tables)

CAPITAL STOCK (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
SCHEDULE OF STOCK OPTION ACTIVITY	The following table summarizes common stock option activity: SCHEDULE OF STOCK OPTION ACTIVITY Options Weighted Average Exercise Price Outstanding, December 31, 2022 1,250,000 $ 1.10 Granted 1,400,000 $ 0.40 Exercised - - Expired - - Expired / Forfeited (283,333 ) 1.10 Outstanding, December 31, 2023 2,650,000 $ 0.73 Exercisable, December 31, 2023 1,812,500 $ 0.73 Outstanding, December 31, 2023 2,650,000 $ 0.73 Granted - $ - Exercised - - Expired / Forfeited (283,333 ) 1.10 Outstanding, June 30, 2024 2,366,667 $ 0.69 Exercisable, June 30, 2024 1,979,167 $ 0.61	The following table summarizes common stock options activity: The following table summarizes common stock options activity: SCHEDULE OF STOCK OPTION ACTIVITY Options Weighted Average Exercise Price December 31, 2021 - $ - Granted 1,250,000 1.10 Exercised - - Expired - - Outstanding, December 31, 2022 1,250,000 $ 1.10 Exercisable, December 31, 2022 133,333 $ 1.10 Outstanding, December 31, 2023 1,250,000 $ 1.10 Granted 1,400,000 $ 0.40 Exercised - - Expired - - Outstanding, December 31, 2023 2,650,000 $ 0.73 Exercisable, December 31, 2023 1,812,500 $ 0.73 The weighted average exercise prices, remaining lives for options granted, and exercisable as of December 31, 2023 were as follows: Outstanding Options Exercisable Options Options Exercise Price Per Share Shares Life (Years) Weighted Average Exercise Price Shares Weighted Average Exercise Price $ 1.10 1,400,000 4.28 $ 1.10 562,500 $ 1.10 $ 0.32 1,250,000 5.00 $ 0.32 1,250,000 $ 0.32
SCHEDULE OF OPTIONS FAIR VALUE ASSUMPTIONS	SCHEDULE OF OPTIONS FAIR VALUE ASSUMPTIONS Fair Value of Common Stock on measurement date $ 0.99 0.29 Risk free interest rate 3.83 3.30 % Volatility 232.05 92.54 % Dividend Yield 0 % Expected Term 6.0 3.5 (1) The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date. (2) The trading volatility was determined by calculating the volatility of the Company’s peer group. (3) The Company does not expect to pay a dividend in the foreseeable future (4) The Company, in accordance with staff accounting bulletin (“ SAB	SCHEDULE OF FAIR VALUE ASSUMPTIONS Fair Value of Common Stock on measurement date $ 1.00 0.32 Risk free interest rate 3.83 3.30 % Volatility 232.05 92.54 % Dividend Yield 0 % Expected Term 6.0 3.5 (1) The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date. (2) The trading volatility was determined by calculating the volatility of the Company’s peer group. (3) The Company does not expect to pay a dividend in the foreseeable future (4) The Company, in accordance with staff accounting bulletin (“SAB”)14-D.2, used the simplified method (plain vanilla) to determine the overall expected term
SCHEDULE OF WARRANT ACTIVITY	The following table summarizes common stock warrants activity: SCHEDULE OF WARRANT ACTIVITY Warrants Weighted Average Exercise Price Outstanding, December 31, 2022 2,000,000 $ 1.00 Granted 367,500 1.22 Exercised (1,024,500 ) 1.00 Expired - - Cancelled - - Outstanding, December 31, 2023 1,343,000 1.41 Exercisable, December 31, 2023 1,343,000 1.41 Outstanding, December 31, 2023 1,343,000 1.41 Granted 4,842,000 0.39 Exercised - - Expired - - Cancelled - - Outstanding, June 30, 2024 6,185,000 0.55 Exercisable, June 30, 2024 6,185,000 $ 0.55	The following table summarizes common stock warrants activity: SCHEDULE OF WARRANT ACTIVITY Warrants Weighted Average Exercise Price Outstanding, December 31, 2021 - $ - Granted 2,210,070 1.00 Exercised - - Expired - - Cancelled (210,070 ) 1.00 Outstanding, December 31, 2022 2,000,000 1.00 Exercisable, December 31, 2022 2,000,000 $ 1.00 Granted 367,500 1.22 Exercised (1,024,500 ) 1.00 Expired - - Cancelled - - Outstanding, December 31, 2023 1,343,000 1.43 Exercisable, December 31, 2023 1,343,000 $ 1.43 The weighted average exercise prices, remaining lives for warrants granted, and exercisable as of December 31, 2023, were as follows: Outstanding and Vested Warrants Weighted Average Warrant Exercise Price Per Share Shares Life (Years) $ 1.43 1,343,000 2.07
SCHEDULE OF SHARE PURCHASE AGREEMENT	On April 28, 2024, the Company and the Purchaser entered into an Omnibus Amendment Agreement No. 1, which amended the SPA to, adjust the closings which were to take place under the SPA as follows: SCHEDULE OF SHARE PURCHASE AGREEMENT # Initial Stated Warrants Closing Date Aggregate Initial Closing $ 550,000 3,300,000 Initial Closing Date $ 500,000 Second Closing $ 275,000 On or before June 30, 2024 $ 250,000 Third Closing $ 825,000 1,500,000 On or before June 30, 2024 $ 750,000 Fourth Closing $ 1,100,000 Such date as is no later than 180 days after the shares of Common Stock issuable in respect of the Series B Preferred Stock sold in each of the Initial Closing, Second Closing, the Third Closing, and the Fourth Closing have been registered under the Securities Act, subject to any limitations pursuant to Rule 415 $ 1,000,000.00 Total $ 2,750,000 4,800,000 $ 2,500,000
SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE	The weighted average exercise prices, remaining lives for options granted, and exercisable as of June 30, 2024 were as follows: SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE Outstanding Exercisable Options Options Exercise Price Per Shares Life (Years) Weighted Average Exercise Shares Weighted Average Exercise $ 1.10 1,116,667 4.03 $ 1.10 729,167 $ 1.10 $ 0.32 1,250,000 4.50 $ 0.32 1,250,000 $ 0.32
SCHEDULE OF WARRANTS OUTSTANDING AND EXERCISABLE	The weighted average exercise prices, remaining lives for warrants granted, and exercisable as of June 30, 2024, were as follows: SCHEDULE OF WARRANTS OUTSTANDING AND EXERCISABLE Outstanding and Vested Warrants Weighted Average Shares Life (Years) $ 0.55 6,185,000 4.30
SCHEDULE OF WARRANTS FAIR VALUE ASSUMPTIONS	SCHEDULE OF WARRANTS FAIR VALUE ASSUMPTIONS Fair Value of Common Stock on measurement date $ 0.21 0.73 Risk-free interest rate From 2.95 4.38 % Volatility From 81.92 239.06 % Dividend Yield 0 % Expected Term 5 (1) The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date. (2) The trading volatility was determined by calculating the volatility of the Company’s peer group. (3) The Company does not expect to pay a dividend in the foreseeable future.
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
SCHEDULE OF OPTIONS FAIR VALUE ASSUMPTIONS		SCHEDULE OF FAIR VALUE ASSUMPTIONS Fair Value of Common Stock on measurement date $ 0.37 0.97 Risk-free interest rate From 2.95 4.00 % Volatility From 81.92 169.22 % Dividend Yield 0 % Expected Term 5 (1) The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date. (2) The trading volatility was determined by calculating the volatility of the Company’s peer group. (3) The Company does not expect to pay a dividend in the foreseeable future.

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
SCHEDULE OF MATURITY OF LEASE LIABILITIES	SCHEDULE OF MATURITY OF LEASE LIABILITIES Maturity of Lease Liabilities at June 30, 2024 Amount 2024 $ 35,950 2025 67,589 Total lease payments 103,539 Less: Imputed interest (5,994 ) Present value of lease liabilities $ 97,545	SCHEDULE OF MATURITY OF LEASE LIABILITIES Maturity of Lease Liabilities at December 31, 2023 Amount 2024 $ 71,716 2025 67,589 Later years - Total lease payments 139,305 Less: Imputed interest (10,626 ) Present value of lease liabilities $ 128,679

INCOME TAXES (Tables)

INCOME TAXES (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Income Tax Disclosure [Abstract]
SCHEDULE OF DEFERRED TAX ASSET		The Company has a deferred tax asset as shown in the following: SCHEDULE OF DEFERRED TAX ASSET Year Ending December 31, 2023 Year Ending December 31, 2022 Deferred Tax Asset 11,228,173 2,015,756 Valuation Allowance (11,228,173 ) (2,015,756 ) Net Deferred Tax Asset $ — $ —
SCHEDULE OF SHARE PURCHASE AGREEMENT	On April 28, 2024, the Company and the Purchaser entered into an Omnibus Amendment Agreement No. 1 (the “ Amendment SCHEDULE OF SHARE PURCHASE AGREEMENT # Initial Stated Warrants Closing Date Aggregate Initial Closing $ 550,000 3,300,000 Initial Closing Date $ 500,000 Initial Closing Amount Second Closing $ 275,000 On or before June 30, 2024 Second Closing Date $ 250,000 Second Closing Amount Third Closing $ 825,000 1,500,000 On or before June 30, 2024 $ 750,000 Third Closing Amount Fourth Closing $ 1,100,000 Such date as is no later than 180 days (the “ Fourth Closing Date Securities Act $ 1,000,000.00 Fourth Closing Amount Total $ 2,750,000 4,800,000 $ 2,500,000

ORGANIZATION AND DESCRIPTION _2

ORGANIZATION AND DESCRIPTION OF THE BUSINESS (Details Narrative) - USD ($)															1 Months Ended	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 28, 2024	May 24, 2024	May 24, 2024	May 22, 2024	May 21, 2024	May 17, 2024	Apr. 26, 2024	Apr. 24, 2024	Apr. 08, 2024	Apr. 05, 2024	Jan. 18, 2024	Dec. 19, 2023	Dec. 15, 2023	Mar. 22, 2023	Mar. 31, 2023	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Apr. 04, 2024	Jan. 22, 2024	Mar. 20, 2023
Proceeds from sale of common stock																				$ 568,270	$ 5,000,000	$ 6,200,000	$ 2,000,000
Number of shares issued, value																$ 388,270	$ 180,000	$ 1,024,500	$ 5,000,000			$ 6,200,000
Mango Rx Mexico [Member]
Equity ownership percentage																98%				98%
Mango Rx U K Limited [Member]
Equity ownership percentage																100%				100%
Series B Preferred Stock [Member]
Number of shares issued		1,923,644	150	155	50
Purchase price		$ 0.203	$ 0.203
Number of shares sold	1,000
Number of shares issued, value		$ 390,500	$ 165,000	$ 170,500	$ 55,000
Series B Preferred Stock [Member] | Thrid Closing Date [Member]
Number of shares sold	750
Underwriters [Member]
Number of shares issued											600,000
Proceeds from sale of common stock											$ 160,000
Common Stock [Member]
Number of shares issued												4,000,000				950,000	600,000	1,024,500	1,250,000			5,250,000
Number of shares sold												4,000,000		1,250,000
Issuance of shares												$ 1,200,000		$ 5,000,000
Offering expense												$ 1,000,000
Number of shares issued, value																$ 95	$ 60	$ 102	$ 125			$ 525
Share price												$ 0.30		$ 4
Warrant [Member]
Number of shares issued, value
Warrant One [Member] | Thrid Closing Date [Member]
Number of warrants to purchase of common stock	1,000,000
Exercise price per share	$ 0.50
Warrant Two [Member] | Thrid Closing Date [Member]
Number of warrants to purchase of common stock	500,000
Exercise price per share	$ 1
Underwriting Agreement [Member]
Number of warrants to purchase of common stock																									42,000
Exercise price per share												$ 0.38													$ 0.375
Underwriting Agreement [Member] | Common Stock [Member]
Purchase price													$ 0.30
Underwriting Agreement [Member] | Warrant [Member]
Number of warrants to purchase of common stock												280,000													42,000
Underwriting Agreement [Member] | Warrant Two [Member]
Exercise price per share	1
Underwriting Agreement [Member] | Boustead Securities L L C [Member]
Number of shares issued													4,000,000
Securities Purchase Agreement [Member] | Series B Preferred Stock [Member]
Number of shares issued										1,500
Number of shares sold						100	150			500
Number of shares issued, value										$ 1,650,000
Sale of stock value						$ 100,000	$ 150,000
Securities Purchase Agreement [Member] | Warrant [Member]
Exercise price per share	0.50																							$ 0.26
Warrants to purchase common stock										3,300,000														3,300,000
Purchase price of warrants										$ 1,500,000
Aggregate amount for warrant										$ 500,000
Securities Purchase Agreement [Member] | Warrant One [Member]
Exercise price per share	$ 1
Equity Purchase Agreement [Member]
Number of shares issued				700,000	250,000				1,000,000	1,000,000
Purchase price				$ 0.48	$ 0.48
Number of shares issued, value				$ 337,915	$ 119,750				$ 25,000,000	$ 25,000,000
I P Purchase Agreement [Member] | Series C Preferred Stock [Member]
Number of shares issued								980,000
Number of shares issued, value								$ 19,600,000
Share price								$ 20
Consideration amount								$ 20,000,000
Cash								$ 400,000
Cumulative preferred stock description								(i) with $200,000 payable on or before June 30, 2024, which was timely paid, (ii) $100,000 payable on or before August 31, 2024, and (iii) $100,000 payable on or before November 30, 2024.
IPO [Member]
Number of shares issued															1,250,000
Purchase price															$ 4				$ 4
Proceeds from sale of common stock															$ 4,350,000
IPO [Member] | Common Stock [Member]
Number of warrants to purchase of common stock												280,000														87,500
Exercise price per share												$ 0.38														$ 5
Resale Prospectus [Member]
Number of shares issued															2,000,000
Purchase price															$ 1				$ 1
Number of shares sold															4,765,000
Over-Allotment Option [Member] | Underwriters [Member]
Number of shares issued											4,600,000
Over-Allotment Option [Member] | Underwriting Agreement [Member] | Common Stock [Member]
Number of shares issued													600,000
Commitment Shares [Member] | Equity Purchase Agreement [Member]
Number of shares issued, value									$ 214,900	$ 214,900
Share price									$ 0.2149	$ 0.2149

SCHEDULE OF FINANCIAL INSTRUMEN

SCHEDULE OF FINANCIAL INSTRUMENTS MEASUREMENT AT FAIR VALUE (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Fair Value, Inputs, Level 1 [Member]
Platform Operator, Crypto Asset [Line Items]
Cash	$ 490,243	$ 739,006	$ 682,860
Total assets	490,243	739,006	682,860
Total liabilities
Fair value, net asset (liability)	490,243	739,006	682,860
Total assets	490,243	739,006	682,860
Fair value, net asset (liability)	490,243	739,006	682,860
Fair Value, Inputs, Level 2 [Member]
Platform Operator, Crypto Asset [Line Items]
Cash
Total assets
Total liabilities
Fair value, net asset (liability)
Total assets
Fair value, net asset (liability)
Fair Value, Inputs, Level 3 [Member]
Platform Operator, Crypto Asset [Line Items]
Cash
Total assets
Total liabilities
Fair value, net asset (liability)
Total assets
Fair value, net asset (liability)

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Cash, FDIC insured amount	$ 250,000		$ 250,000		$ 250,000
Cash equivalents	0		0		0	$ 0
Inventory write-downs			0	$ 0	0	0
Marketing and advertising expense	$ 229,244	$ 797,263	1,081,627	$ 912,997	$ 2,097,505	$ 352,860
Impairment of indefinite lived intangible assets			$ 0
Mango Rx U K Limited [Member]
Property, Plant and Equipment [Line Items]
Equity method investment ownership percentage.	100%		100%
Mango Rx U K Limited [Member] | Mango Rx I P Holdings L L C [Member]
Property, Plant and Equipment [Line Items]
Equity method investment ownership percentage.	98%		98%
Minimum [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment estimated useful lives	3 years		3 years		3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment estimated useful lives	5 years		5 years		5 years
Options [Member]
Property, Plant and Equipment [Line Items]
Anti-dilutive securities			2,366,667		2,650,000	1,250,000
Warrant [Member]
Property, Plant and Equipment [Line Items]
Anti-dilutive securities			6,185,000		1,343,000	2,000,000
Derivative [Member]
Property, Plant and Equipment [Line Items]
Anti-dilutive securities			0		0

PREPAID EXPENSES-RELATED PART_2

PREPAID EXPENSES-RELATED PARTIES (Details Narrative) - USD ($)	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022	Oct. 01, 2022
Prepaid Expenses-related Parties
Prepaid expenses related party	$ 13,299	$ 60,953	$ 11,745
Security deposits				$ 16,942

INVENTORY (Details Narrative)

INVENTORY (Details Narrative) - USD ($)	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Inventory	$ 14,019	$ 18,501

SCHEDULE OF PROPERTY PLANT AND

SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Less accumulated depreciation:	$ (1,749)	$ (28,752)	$ (3,863)
Property and equipment, net	3,313	96,129	117,499
Computers	5,062	5,062
Equipment	119,819	119,819
Disposed equipment	$ (119,819)	119,819
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Equipment		5,062	5,062
Equipment [Member]
Property, Plant and Equipment [Line Items]
Equipment		$ 119,819	$ 116,300

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT (Details Narrative) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	May 15, 2024
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 9,429	$ 12,306	$ 24,889	$ 3,863
Total net property plant and equipment	3,313		96,129	117,499
Acquired computers and office equipment		3,519	$ 3,519	$ 43,102
Depreciation	1,749	$ 6,082
Disposed equipment					$ 119,819
Equipment was sold	65,000
Realizing a loss on sale of assets	$ 18,837

LOANS FROM RELATED PARTIES (Det

LOANS FROM RELATED PARTIES (Details Narrative) - USD ($)						6 Months Ended		12 Months Ended
	Aug. 18, 2022	Jun. 29, 2022	Jun. 16, 2022	Mar. 18, 2022	Dec. 10, 2021	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Apr. 01, 2024	Mar. 18, 2024	Mar. 01, 2024
Related Party Transaction [Line Items]
Proceeds from issuance of common stock						$ 568,270	$ 5,000,000	$ 6,200,000	$ 2,000,000
Repayment of related party debt							89,200	89,200	25,070
Proceeds from related party						187,500			75,000
Ronin Equity Partners [Member]
Related Party Transaction [Line Items]
Borrow amount												$ 37,500
Cohen Enterprises Inc [Member]
Related Party Transaction [Line Items]
Borrow amount										$ 100,000	$ 50,000
Cohen Enterprises [Member]
Related Party Transaction [Line Items]
Related party advances received		$ 25,000
Cohen Enterprises Inc [Member]
Related Party Transaction [Line Items]
Issuance of shares			8,000,000
Equity ownership interest			80%
Proceeds from issuance of common stock			$ 90,000
Repayment of related party debt	$ 25,000								89,200
Proceeds from related party						$ 0		0
Imputed interest percentage						8%
Related party transaction purchases						$ 8,232
Zip Doctor Inc [Member]
Related Party Transaction [Line Items]
Related party advances received					$ 25,000
Cohen Enterprises Inc [Member]
Related Party Transaction [Line Items]
Issuance of shares			8,000,000
Proceeds from issuance of common stock			$ 90,000
Repayment of related party debt	$ 25,000								89,200
Proceeds from related party								$ 0	89,200
Imputed interest percentage								8%
Related party transaction purchases								$ 8,232
Zip Doctor Inc [Member]
Related Party Transaction [Line Items]
Related party advances received					70
Repayment of related party debt								$ 0	$ 70
Imputed interest percentage								8%
Stock Purchase Agreement [Member]
Related Party Transaction [Line Items]
Related party advances received				$ 50,000	$ 39,200	$ 89,200		$ 89,200
Repayment of related party debt			$ 89,200

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - USD ($)			2 Months Ended	6 Months Ended		12 Months Ended
	Apr. 01, 2023	Mar. 23, 2023	Mar. 01, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Nov. 18, 2022
Debt Disclosure [Abstract]
Debt instrument face amount								$ 78,260
Debt instrument periodic payment	$ 31,630		$ 5,000
Repayments of notes payable		$ 63,260			$ 78,260	$ 78,260
Notes payable

SCHEDULE OF STOCK OPTION ACTIVI

SCHEDULE OF STOCK OPTION ACTIVITY (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options, Outstanding Beginning Balance	2,650,000	1,250,000
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 0.73	$ 1.10
Options, Granted		1,400,000	1,250,000
Weighted Average Exercise Price, Granted		$ 0.40	$ 1.10
Options, Exercised
Weighted Average Exercise Price, Exercised
Options, Expired	283,333
Weighted Average Exercise Price, Expired	$ 1.10
Options, Outstanding Ending Balance	2,366,667	2,650,000	1,250,000
Weighted Average Exercise Price, Outstanding Ending Balance	$ 0.69	$ 0.73	$ 1.10
Options, Exercisable Ending Balance	1,979,167	1,812,500	133,333
Weighted Average Exercise Price, Exercisable Ending Balance	$ 0.61	$ 0.73	$ 1.10
Options, Expired	(283,333)
Range One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options, Outstanding Beginning Balance	1,400,000
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 1.10
Options, Outstanding Ending Balance	1,116,667	1,400,000
Weighted Average Exercise Price, Outstanding Ending Balance	$ 1.10	$ 1.10
Options, Exercisable Ending Balance	729,167	562,500
Weighted Average Exercise Price, Exercisable Ending Balance	$ 1.10	$ 1.10
Options Term	4 years 10 days	4 years 3 months 10 days
Range Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options, Outstanding Beginning Balance	1,250,000
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 0.32
Options, Outstanding Ending Balance	1,250,000	1,250,000
Weighted Average Exercise Price, Outstanding Ending Balance	$ 0.32	$ 0.32
Options, Exercisable Ending Balance	1,250,000	1,250,000
Weighted Average Exercise Price, Exercisable Ending Balance	$ 0.32	$ 0.32
Options Term	4 years 6 months	5 years

SCHEDULE OF FAIR VALUE ASSUMPTI

SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Dividend rate	0%	0%
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Dividend rate	0%	0%
Expected term	5 years	5 years
Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Fair Value of Common Stock on measurement date	$ 0.99	$ 1
Risk-free interest rate	3.83%	3.83%
Volatility	232.05%	232.05%
Expected term	6 years	6 years
Maximum [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Fair Value of Common Stock on measurement date	$ 0.73	$ 0.97
Risk-free interest rate	4.38%	4%
Volatility	239.06%	169.22%
Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Fair Value of Common Stock on measurement date	$ 0.29	$ 0.32
Risk-free interest rate	3.30%	3.30%
Volatility	92.54%	92.54%
Expected term	3 years 6 months	3 years 6 months
Minimum [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Fair Value of Common Stock on measurement date	$ 0.21	$ 0.37
Risk-free interest rate	2.95%	2.95%
Volatility	81.92%	81.92%

SCHEDULE OF WARRANT ACTIVITY (D

SCHEDULE OF WARRANT ACTIVITY (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted Average Exercise Price Exercised		$ 1.43
Outstanding and Vested Warrants Expected Term	4 years 3 months 18 days
Warrants Outstanding, Ending balance	6,185,000
Weighted Average Exercise Price Ending Balance	$ 0.55
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants Beginning Balance	1,343,000	2,000,000
Weighted Average Exercise Price Beginning Balance	$ 1.43	$ 1
Warrants Granted		367,500	2,210,070
Weighted Average Exercise Price Granted		$ 1.22	$ 1
Warrants Exercised		(1,024,500)
Weighted Average Exercise Price Exercised		$ 1
Warrants Expired
Weighted Average Exercise Price Expired
Warrants Cancelled			(210,070)
Weighted Average Exercise Price Cancelled			$ 1
Warrants Outstanding, Ending balance		1,343,000	2,000,000
Weighted Average Exercise Price Ending Balance		$ 1.43	$ 1
Warrants Exercisable Ending balance		1,343,000	2,000,000
Weighted Average Exercise Price Exercisable price	$ 0.55	$ 1.41	$ 1
Weighted Average Exercise Price Exercisable price		$ 1.43
Outstanding and Vested Warrants Ending balance	6,185,000	1,343,000
Outstanding and Vested Warrants Expected Term	4 years 3 months 18 days	2 years 25 days
Warrants Beginning Balance	1,343,000	2,000,000
Weighted Average Exercise Price Beginning Balance	$ 1.41	$ 1
Warrants Granted	4,842,000	367,500
Weighted Average Exercise Price Granted	$ 0.39	$ 1.22
Warrants Exercised		(1,024,500)
Weighted Average Exercise Price Exercised		$ 1
Warrants Expired
Weighted Average Exercise Price Expired
Warrants Cancelled
Weighted Average Exercise Price Cancelled
Warrants Outstanding, Ending balance	6,185,000	1,343,000	2,000,000
Weighted Average Exercise Price Ending Balance	$ 0.55	$ 1.41	$ 1
Warrants Exercisable Ending balance	6,185,000	1,343,000

CAPITAL STOCK (Details Narrativ

CAPITAL STOCK (Details Narrative) - USD ($)																																																		1 Months Ended	2 Months Ended	3 Months Ended				4 Months Ended		6 Months Ended		12 Months Ended
	Jun. 28, 2024	Jun. 05, 2024	May 24, 2024	May 24, 2024	May 23, 2024	May 22, 2024	May 21, 2024	May 17, 2024	Apr. 26, 2024	Apr. 25, 2024	Apr. 24, 2024	Apr. 18, 2024	Apr. 08, 2024	Apr. 05, 2024	Apr. 04, 2024	Mar. 21, 2024	Feb. 07, 2024	Jan. 22, 2024	Jan. 18, 2024	Jan. 11, 2024	Jan. 10, 2024	Jan. 02, 2024	Dec. 28, 2023	Dec. 19, 2023	Dec. 15, 2023	Dec. 11, 2023	Nov. 15, 2023	Nov. 01, 2023	Oct. 10, 2023	Oct. 01, 2023	Jun. 27, 2023	Jun. 22, 2023	Jun. 21, 2023	Jun. 08, 2023	Jun. 07, 2023	Jun. 06, 2023	Jun. 05, 2023	Jun. 01, 2023	May 25, 2023	May 01, 2023	Apr. 26, 2023	Apr. 25, 2023	Apr. 24, 2023	Apr. 01, 2023	Mar. 22, 2023	Mar. 20, 2023	Jan. 24, 2023	Jan. 06, 2023	Jan. 03, 2023	Mar. 31, 2023	Mar. 01, 2023	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Dec. 22, 2022	Dec. 12, 2022	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Mar. 28, 2024	Aug. 31, 2022	Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares authorized																																																				10,000,000						10,000,000		10,000,000	10,000,000
Preferred stock, par value																																																				$ 0.0001						$ 0.0001		$ 0.0001	$ 0.0001
Common stock, shares authorized																																																				200,000,000						200,000,000		200,000,000	200,000,000
Common stock, par value																																																				$ 0.0001						$ 0.0001		$ 0.0001	$ 0.0001
Common stock, shares issued																																																				29,135,451						29,135,451		21,419,500	13,365,000
Common stock, shares outstanding																																																				29,135,451						29,135,451		21,419,500	13,365,000
Number of shares issued value																																																				$ 388,270	$ 180,000	$ 1,024,500	$ 5,000,000					$ 6,200,000
Debt instrument periodic payment																																												$ 31,630							$ 5,000
Shares issued value																																																				$ 808,400	416,500	387,000	$ 700,000					$ 1,530,651	$ 540,065
Number of options																																																				2,366,667						2,366,667		2,650,000	1,250,000
Number of options granted																																																												1,400,000	1,250,000
Exercise price																																																				$ 0.69						$ 0.69		$ 0.73	$ 1.10
Share based compensation																																																										$ 88,945	$ 128,542	$ 624,463	$ 234,088
Fair value of options outstanding																																																												573,202
Fair value of warrants																																														$ 31,995
Proceeds from sale of common stock																																																										568,270	5,000,000	$ 6,200,000	$ 2,000,000
Number of options unvested	216,667																																																													283,333
Share based compensation																																																										88,945	$ 131,113
Exercisable options outstanding																																																				$ 811,261						$ 811,261
Number of shares issued upon exercise
Outstanding and vested warrants expected term																																																										4 years 3 months 18 days
Series B Convertible Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares authorized																																																				6,000						6,000		6,000		6,000
Preferred stock, par value																																																				$ 0.0001						$ 0.0001		$ 0.0001		$ 0.0001
Preferred stock stated value																																																														$ 1,100
Preferred stock, shares issued																																																				2,145						2,145		0
Preferred stock, shares outstanding																																																				2,145						2,145		0
Series B Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued value			$ 390,500	$ 165,000		$ 170,500	$ 55,000
Number of shares issued			1,923,644	150		155	50
Shares price per share			$ 0.203	$ 0.203
Number of shares sold	1,000
Number of converted shares				812,807		839,901	270,936
Conversion price				$ 0.203		$ 0.203	$ 0.203
Number of converted shares			355
Six Percentage Series C Convertible Cumulative Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, par value												$ 0.0001
Number of shares issued												6,250,000
Preferred stock, shares issued																																																				980,000						980,000		0
Preferred stock, shares outstanding																																																				980,000						980,000		0
Investor [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Fair value of warrants outstanding																																																				$ 1,735,966						$ 1,735,966		$ 852,480	$ 581,264
General and Administrative Expense [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share based compensation																																																												$ 624,463	$ 82,267
Twenty Twenty Two Equity Incentive Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued value		$ 437,500
Shares price per share		$ 0.35
Private Placement Warrant One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants to purchase of common stock																																				150,000							100,000
Sale of stock price																																				$ 1							$ 1
Consideration paid																																				$ 150,000							$ 100,000
Private Placement Warrant Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants to purchase of common stock																																			75,000							100,000
Sale of stock price																																			$ 1							$ 1
Consideration paid																																			$ 75,000							$ 100,000
Private Placement Warrant Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants to purchase of common stock																																		24,500								25,000
Sale of stock price																																		$ 1								$ 1
Consideration paid																																		$ 24,500								$ 25,000
Private Placement Warrant Four [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants to purchase of common stock																																	100,000									25,000
Sale of stock price																																	$ 1									$ 1
Consideration paid																																	$ 100,000									$ 25,000
Private Placement Warrant Five [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants to purchase of common stock																																100,000										75,000
Sale of stock price																																$ 1										$ 1
Consideration paid																																$ 100,000										$ 75,000
Private Placement Warrant Six [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants to purchase of common stock																															100,000										100,000
Sale of stock price																															$ 1										$ 1
Consideration paid																															$ 100,000										$ 100,000
Private Placement Warrant Seven [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants to purchase of common stock																																								25,000
Sale of stock price																																								$ 1
Consideration paid																																								$ 25,000
Private Placement Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares price per share																																																															$ 1
Number of warrants to purchase of common stock																																					25,000
Sale of stock price																																					$ 1
Consideration paid																																					$ 25,000
Exercise price per share																																																															$ 1
Fair value of warrants outstanding																																																															$ 2,000,000
Exercise of warrants shares																																																				975,500						975,500		975,500
IPO [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued																																																		1,250,000
Shares price per share																																																		$ 4					$ 4
Proceeds from sale of common stock																																																		$ 4,350,000
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued value																																																				$ 95	$ 60	$ 102	$ 125					$ 525
Number of shares issued																								4,000,000																												950,000	600,000	1,024,500	1,250,000					5,250,000
Number of shares sold																								4,000,000																					1,250,000
Share price																								$ 0.30																					$ 4
Gross proceeds																								$ 1,200,000																					$ 5,000,000
Shares issued in consideration																																																				2,642,308	1,600,000	375,000	700,000					1,780,000	3,365,000
Shares issued value																																																				$ 264	$ 160	$ 37	$ 70					$ 178	$ 337
Exercise price																							$ 0.32																	$ 1.10
Vesting term																							5 years																	3 years																					3 years
Common Stock [Member] | 2022 Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of options																							1,250,000																	150,000																					1,250,000
Common Stock [Member] | IPO [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants to purchase of common stock																								280,000																						87,500
Exercise price per share																								$ 0.38																						$ 5
Fair value of warrants																								$ 78,174																						$ 31,995
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued value
Shares issued value
Fair value of warrants																								$ 271,216
Exercise of warrants shares																																																												1,063,000
Outstanding and vested warrants expected term																																																												3 years 9 months 29 days
Warrants outstanding																																																				6,185,000						6,185,000		1,343,000
Outstanding and vested warrants expected term																																																										4 years 3 months 18 days		2 years 25 days
Consulting Agreements [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued value																																															$ 350,000
Shares price per share																																															$ 1
Consulting Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued value																														$ 2,000
Number of shares issued																														50,000
Securities Purchase Agreement [Member] | Series B Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued value														$ 1,650,000
Number of shares issued														1,500
Number of shares sold								100	150					500
Consideration paid								$ 100,000	$ 150,000
Securities Purchase Agreement [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price per share	$ 0.50														$ 0.26
Fair value of warrants	$ 260,750														$ 681,352
Fair value of warrants outstanding														$ 500,000
Warrants to purchase common stock														3,300,000	3,300,000
Purchase price of warrants														$ 1,500,000
Number of shares issued upon exercise	1,000,000
Securities Purchase Agreement [Member] | Warrant One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price per share	$ 1
Fair value of warrants	$ 122,341
Number of shares issued upon exercise	500,000
Underwriting Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants to purchase of common stock																		42,000
Exercise price per share																		$ 0.375						$ 0.38
Fair value of warrants																		$ 12,086
Underwriting Agreement [Member] | Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares price per share																									$ 0.30
Underwriting Agreement [Member] | Common Stock [Member] | Over-Allotment Option [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued																									600,000
Underwriting Agreement [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants to purchase of common stock																		42,000						280,000
Underwriting Agreement [Member] | Warrant Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price per share	$ 1
I P Purchase Agreement [Member] | Six Percentage Series C Convertible Cumulative Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued value											$ 19,600,000
Number of shares issued											980,000
Share price											$ 20
Consideration amount											$ 20,000,000
Cash											$ 400,000
Cumulative preferred stock description											(i) with $200,000 payable on or before June 30, 2024, (ii) $100,000 payable on or before August 31, 2024, and (iii) $100,000 payable on or before November 30, 2024.
Equity Purchase Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued value						$ 337,915	$ 119,750						$ 25,000,000	$ 25,000,000
Number of shares issued						700,000	250,000						1,000,000	1,000,000
Shares price per share						$ 0.48	$ 0.48
Equity Purchase Agreement [Member] | Commitment Shares [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued value													$ 214,900	$ 214,900
Share price													$ 0.2149	$ 0.2149
Mrs.Hammer [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Annual salary																																								$ 150,000
Exercise price																																								$ 1
Shares vesting																																								50,000
Stock options description																																								The Employment Agreement also required the Company to grant Mrs. Hammer a sign-on bonus of (a) 75,000 restricted shares of common stock of the Company, vested in full upon issuance, and (b) options to purchase an additional 150,000 shares of common stock of the Company, under the Company’s 2022 Equity Incentive Plan (the “Plan”), with an exercise price of the greater of (i) $1.10 per share; and (ii) the closing sales price of the Company’s common stock on the Nasdaq Capital Market on the date the Employment Agreement and the grant is approved by the Board (which date was May 1, 2023), and which exercise price was $1.00 per share, with options to purchase 50,000 shares vesting every twelve months that the Employment Agreement is in effect, subject to the terms of the Plan. The options are exercisable for a period of ten years and are documented by a separate option agreement entered into by the Company and Mrs. Hammer.
Chief Executive Officer [Member] | Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price																																																													$ 1.10
Chief Executive Officer [Member] | Common Stock [Member] | 2022 Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of options granted																																																													750,000
Chief Operating Officer [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued		100,000
Chief Operating Officer [Member] | Common Stock [Member] | 2022 Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of options granted																																																													500,000
Underwriters [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued																			600,000
Proceeds from sale of common stock																			$ 160,000
Underwriters [Member] | Over-Allotment Option [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued																			4,600,000
Officers Directors And Employees [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued		1,250,000
Chief Executive Officer And Chairman [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued		800,000
President [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued		50,000
Three Independent Directors [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued		100,000
Twenty Three Accredited Investors [Member] | Private Placement Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued value																																																									$ 2,000,000
Number of shares issued																																																								2,000,000
Restricted Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Settlement description																																															the Company issued an aggregate of 350,000 shares of common stock to the consultants as follows: (1) Sultan Haroon 150,000 shares of restricted common stock; (2) John Helfrich 25,000 shares of restricted common stock; (3) Justin Baker 25,000 shares of restricted common stock; and (4) Maja Matthews 150,000 shares of restricted common stock. The shares issued to Mr. Haroon and Ms. Matthews vest at the rate of 50,000 shares upon entry into the agreement, 50,000 shares upon the Company’s successful launch of a new product category, and 50,000 shares upon the Company’s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement. The shares issued to Mr. Helfrich and Mr. Baker vest at the rate of 10,000 shares upon entry into the agreement, 7,500 shares upon the Company’s successful launch of a new product category, and 7,500 shares upon the Company’s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement.
Restricted Stock [Member] | Private Placement Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued value																																								$ 180,000
Number of shares issued																																								180,000
Share price																																								$ 1
Consideration paid																																								$ 300,000
Restricted Stock [Member] | Dr.Rudman [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued value																																																$ 25,000
Number of shares issued																																																25,000
Shares price per share																																																$ 1
Compensation expense																																																$ 2,000
Restricted Stock [Member] | Mr.Boon [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued value																																																$ 25,000
Number of shares issued																																																25,000
Shares price per share																																																$ 1
Restricted Stock [Member] | Mr Andrew [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued value																																							$ 55,000
Shares price per share																												$ 0.58											$ 1.10
Restricted Stock [Member] | Mr Andrew [Member] | 2022 Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued value																																							$ 55,000
Number of shares issued																																							50,000
Shares price per share																																							$ 1.10
Restricted Stock [Member] | Major Dodge [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued value																																						$ 22,000
Shares price per share																																						$ 1.10
Restricted Stock [Member] | Major Dodge [Member] | 2022 Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued value																																						$ 22,000
Number of shares issued																																						20,000
Shares price per share																																						$ 1.10
Restricted Stock [Member] | Dr Douglas Christianson [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued value																												$ 29,000
Number of shares issued																												50,000
Shares price per share																												$ 0.58
Restricted Stock [Member] | Marius Pharmaceuticals [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued																										100,000
Thrid Closing Date [Member] | Series B Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares sold	750
Thrid Closing Date [Member] | Warrant One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants to purchase of common stock	1,000,000
Exercise price per share	$ 0.50
Thrid Closing Date [Member] | Warrant Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants to purchase of common stock	500,000
Exercise price per share	$ 1
Dojo Labs [Member] | Restricted Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued value																																																	$ 100,000
Number of shares issued																																																	50,000
Shares price per share																																																	$ 1
Bethor Ltd [Member] | Restricted Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued value																																																$ 250,000
Number of shares issued																																																250,000
Shares price per share																																																$ 1
Street Group LLC [Member] | Restricted Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued value																																						$ 55,000
Number of shares issued																																						50,000
Shares price per share																																						$ 1.10
Debt instrument periodic payment																																						$ 5,000
Greentree Financial Group [Member] | Service Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued value																																																										$ 84,750		$ 84,750
Shares price per share																																																				$ 1.13						$ 1.13		$ 1.13
Greentree Financial Group [Member] | Restricted Stock [Member] | Service Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares issued in consideration																																																										75,000		75,000
Shares issued value																																																										$ 40,000		$ 40,000
Settlement description																																																										(a) $20,000 on or before September 30, 2023; (b) $20,000 on or before March 31, 2024		(a) $20,000 on or before September 30, 2023; (b) $20,000 on or before March 31, 2024.
Luca Consulting, LLC [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Settlement description																													(a) $5,000 on the signing of the agreement; (b) $5,000 on the tenth of each month throughout the remainder of the agreement.
Luca Consulting, LLC [Member] | Consulting Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued value																													$ 126,000
Number of shares issued																													200,000
Shares price per share																$ 0.1975					$ 0.28								$ 0.63
Shares issued value																													$ 15,000
Settlement description																													(a) $5,000 on the signing of the agreement; (b) $5,000 on the tenth of each month throughout the remainder of the agreement.
Number of restricted shares issued																500,000					200,000
Number of restricted stock value																$ 98,750					$ 56,000
Agreement payable in cash																$ 5,000					$ 15,000
Consulting agreement description																					(a) $5,000 on the signing of the agreement; and (b) $5,000 on the tenth of each month throughout the remainder of the agreement. The Service Agreement includes customary indemnification obligations requiring the Company to indemnify Luca and its affiliates with regard to certain matters.
Jason Szkup [Member] | Restricted Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued value																												$ 17,400
Number of shares issued																												30,000
Shares price per share																												$ 0.58
Shares issued value																												$ 10,000
PHX Global LLC [Member] | Two Thousand Twenty Two Equity Incentive Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares price per share										$ 0.28
Number of restricted shares issued										200,000
Number of restricted stock value										$ 56,000
PHX Global LLC [Member] | Restricted Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued value																											$ 94,000
Number of shares issued																											200,000
Shares price per share																											$ 0.47
Number of restricted shares issued										200,000
Marius Pharmaceuticals [Member] | Restricted Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued value																										$ 58,000
Number of shares issued																										100,000
Shares price per share																										$ 0.58
G&P General Consulting [Member] | Consulting Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares price per share																						$ 0.28
Number of restricted shares issued																						250,000
Number of additional restricted common shares issued																						500,000
Number of restricted stock value																						$ 70,000
G&P General Consulting [Member] | Consulting Agreement [Member] | Twenty Twenty Two Equity Incentive Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares price per share																	$ 0.41
Number of restricted shares issued																	250,000
Number of restricted stock value																	$ 102,500
First Level Capital [Member] | Consulting Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares price per share																				$ 0.29
Number of restricted shares issued																				250,000
Number of additional restricted common shares issued																				250,000
Number of restricted stock value																				$ 144,950
Agreement payable in cash																				$ 60,000
Consulting agreement description																				(a) $60,000 on the signing of the agreement; and (b) $60,000 on the approval by the Company. The Service Agreement includes customary indemnification obligations requiring the Company to indemnify First Level and its affiliates with regard to certain matters.
Zvonimir Moric Consulting [Member] | Consulting Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares price per share																$ 0.1975
Number of restricted shares issued																150,000
Number of restricted stock value																$ 29,625
Acorn Management Partners L L C [Member] | Consulting Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued					192,308
Shares price per share					$ 0.52
Shares issued value					$ 100,000

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 2,390,979		$ 2,284,025		$ 4,758,560	$ 4,844,910	$ 9,212,417	$ 1,998,055
Accumulated deficit	15,986,733				15,986,733		11,228,173	2,015,756
Net loss	$ 2,391,319	$ 2,367,617	$ 2,284,025	$ 2,560,885	$ 4,758,936	$ 4,844,910	$ 9,212,417	$ 1,998,055

SCHEDULE OF MATURITY OF LEASE L

SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
2025	$ 67,589	$ 71,716
2025		67,589
Later years
Total lease payments	103,539	139,305
Less: Imputed interest	(5,994)	(10,626)
Present value of lease liabilities	97,545	$ 128,679
2024	$ 35,950

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Narrative)		6 Months Ended	12 Months Ended
	Sep. 28, 2022 USD ($) ft²	Jun. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Area of Land | ft²	2,201
Lease term	38 months
Base rent	$ 5,777.63
Percentage of proportionate rent	2.45%
Percentage of incremental borrowing rate	8%
Operating lease, right-of-use asset		$ 90,011	$ 119,262	$ 174,241
Operating lease, liability		97,545	128,679
Operating lease, cost		16,492	65,274
Asset impairment charges		$ 0	$ 0
Operating lease, description	The Lease Agreement has a term of thirty-eight (38) months and has a monthly base rent of $5,777.63, or $31.50 per square foot, from months 3-18 and increases at the rate of $1 per square foot per annum until the end of the lease term
Lease Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Base rent	$ 16,942

SCHEDULE OF DEFERRED TAX ASSET

SCHEDULE OF DEFERRED TAX ASSET (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Deferred Tax Asset	$ 11,228,173	$ 2,015,756
Valuation Allowance	(11,228,173)	(2,015,756)
Net Deferred Tax Asset

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)		12 Months Ended
	Dec. 22, 2017	Dec. 31, 2023	Dec. 31, 2022
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Deferred tax asset net operating loss		$ 9,212,417
Decrease in deferred tax assets, valuation allowance		$ 9,212,417
US federal income corporate tax rates		21%	21%
Net operating loss carry forwards		$ 11,228,173
Maximum [Member]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Statutory federal income tax rate, percentage	35%
Minimum [Member]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Statutory federal income tax rate, percentage	21%

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)

3 Months Ended

6 Months Ended

12 Months Ended

Jul. 30, 2024

Jul. 25, 2024

Jul. 08, 2024

Jun. 28, 2024

May 24, 2024

May 24, 2024

May 22, 2024

May 21, 2024

Mar. 25, 2024

Mar. 21, 2024

Jan. 18, 2024

Jan. 11, 2024

Jan. 10, 2024

Jan. 02, 2024

Dec. 19, 2023

Dec. 15, 2023

Oct. 10, 2023

Oct. 01, 2023

Mar. 22, 2023

Jan. 24, 2023

Jun. 30, 2024

Mar. 31, 2024

Jun. 30, 2023

Mar. 31, 2023

Jun. 30, 2024

Jun. 30, 2023

Dec. 31, 2023

Dec. 31, 2022

Apr. 01, 2024

Mar. 18, 2024

Mar. 01, 2024

Jan. 22, 2024

Subsequent Event [Line Items]

Proceeds from sale of common stock

$ 568,270

$ 5,000,000

$ 6,200,000

$ 2,000,000

Number of stock issued granted

1,400,000

1,250,000

Number of stock issued exercise

Common stock, par value

$ 0.0001

$ 0.0001

$ 0.0001

$ 0.0001

Issuance of common stock for cash

$ 388,270

$ 180,000

$ 1,024,500

$ 5,000,000

$ 6,200,000

Series B Preferred Stock [Member]

Subsequent Event [Line Items]

Share price

$ 0.203

$ 0.203

Number of shares issued

1,923,644

150

155

50

Number of shares sold

1,000

Issuance of common stock for cash

$ 390,500

$ 165,000

$ 170,500

$ 55,000

Warrant [Member]

Subsequent Event [Line Items]

Issuance of common stock for cash

Common Stock [Member]

Subsequent Event [Line Items]

Number of shares issued

4,000,000

950,000

600,000

1,024,500

1,250,000

5,250,000

Number of shares sold

4,000,000

1,250,000

Issuance of common stock for cash

$ 95

$ 60

$ 102

$ 125

$ 525

Underwriters [Member]

Subsequent Event [Line Items]

Number of shares issued

600,000

Proceeds from sale of common stock

$ 160,000

Underwriters [Member] | Over-Allotment Option [Member]

Subsequent Event [Line Items]

Number of shares issued

4,600,000

Luca Consulting, LLC [Member]

Subsequent Event [Line Items]

Settlement description

(a) $5,000 on the signing of the agreement; (b) $5,000 on the tenth of each month throughout the remainder of the agreement.

Ronin Equity Partners [Member]

Subsequent Event [Line Items]

Borrow amount

$ 37,500

Cohen Enterprises Inc [Member]

Subsequent Event [Line Items]

Borrow amount

$ 100,000

$ 50,000

Consulting Agreement [Member]

Subsequent Event [Line Items]

Number of shares issued

50,000

Issuance of common stock for cash

$ 2,000

Consulting Agreement [Member] | G&P General Consulting [Member]

Subsequent Event [Line Items]

Number of restricted common shares issued

250,000

Number of additional restricted common shares issued

500,000

Share price

$ 0.28

Number of restricted common shares issued, value

$ 70,000

Consulting Agreement [Member] | Luca Consulting, LLC [Member]

Subsequent Event [Line Items]

Number of restricted common shares issued

500,000

200,000

Share price

$ 0.1975

$ 0.28

$ 0.63

Number of restricted common shares issued, value

$ 98,750

$ 56,000

Agreement payable in cash

$ 5,000

$ 15,000

Consulting agreement description

(a) $5,000 on the signing of the agreement; and (b) $5,000 on the tenth of each month throughout the remainder of the agreement. The Service Agreement includes customary indemnification obligations requiring the Company to indemnify Luca and its affiliates with regard to certain matters.

Number of shares issued

200,000

Issuance of common stock for cash

$ 126,000

Settlement description

(a) $5,000 on the signing of the agreement; (b) $5,000 on the tenth of each month throughout the remainder of the agreement.

Consulting Agreement [Member] | First Level Capital [Member]

Subsequent Event [Line Items]

Number of restricted common shares issued

250,000

Number of additional restricted common shares issued

250,000

Share price

$ 0.29

Number of restricted common shares issued, value

$ 144,950

Agreement payable in cash

$ 60,000

Consulting agreement description

(a) $60,000 on the signing of the agreement; and (b) $60,000 on the approval by the Company. The Service Agreement includes customary indemnification obligations requiring the Company to indemnify First Level and its affiliates with regard to certain matters.

Consulting Agreement [Member] | Zvonimir Moric Consulting [Member]

Subsequent Event [Line Items]

Number of restricted common shares issued

150,000

Share price

$ 0.1975

Number of restricted common shares issued, value

$ 29,625

Underwriting Agreement [Member]

Subsequent Event [Line Items]

Number of warrants to purchase of common stock

42,000

Exercise price per share

$ 0.38

$ 0.375

Underwriting Agreement [Member] | Warrant [Member]

Subsequent Event [Line Items]

Number of warrants to purchase of common stock

280,000

42,000

Underwriting Agreement [Member] | Common Stock [Member]

Subsequent Event [Line Items]

Share price

$ 0.30

Underwriting Agreement [Member] | Over-Allotment Option [Member] | Common Stock [Member]

Subsequent Event [Line Items]

Number of shares issued

600,000

Consulting Agreements [Member]

Subsequent Event [Line Items]

Share price

$ 1

Issuance of common stock for cash

$ 350,000

Subsequent Event [Member]

Subsequent Event [Line Items]

Common stock, par value

$ 0.0001

Subsequent Event [Member] | Series B Preferred Stock [Member]

Subsequent Event [Line Items]

Share price

$ 0.3267

$ 0.2767

Number of shares sold

10

135

Issuance of common stock for cash

$ 11,000

$ 148,500

Conversion of stock shares converted

33,670

536,682

Subsequent Event [Member] | 2022 Plan [Member]

Subsequent Event [Line Items]

Number of stock available for awards description

The First Amendment increased the number of shares of common stock available for awards under the Incentive Plan, such that currently, subject to adjustment in connection with the payment of a stock dividend, a stock split or subdivision or combination of the shares of common stock, or a reorganization or reclassification of the Company’s common stock, the aggregate number of shares of common stock which may be issued pursuant to awards under the 2022 Plan is currently the sum of (i) 10,000,000, and (ii) an automatic increase on April 1st of each year for a period of nine years commencing on April 1, 2024 and ending on (and including) April 1, 2032, in an amount equal to the lesser of (x) ten percent (10%) of the total shares of common stock of the Company outstanding on the last day of the immediately preceding fiscal year; and (y) 2,000,000 shares of common stock; provided, however, that the Board may act prior to April 1st of a given year to provide that the increase for such year will be a lesser number of shares of common stock. This is also known as an “evergreen” provision. Notwithstanding the foregoing, no more than a total of 26,000,000 shares of common stock (or awards) may be issued or granted under the 2022 Plan in aggregate, and no more than 26,000,000 shares of common stock may be issued pursuant to the exercise of Incentive Stock Options

Number of stock issued

10,000,000

Subsequent Event [Member] | Common Stock [Member] | 2022 Plan [Member]

Subsequent Event [Line Items]

Number of stock issued

2,000,000

Number of stock issued granted

26,000,000

Number of stock issued exercise

26,000,000

Subsequent Event [Member] | Underwriters [Member]

Subsequent Event [Line Items]

Number of shares issued

600,000

Proceeds from sale of common stock

$ 160,000

Subsequent Event [Member] | Underwriters [Member] | Over-Allotment Option [Member]

Subsequent Event [Line Items]

Number of shares issued

4,600,000

Subsequent Event [Member] | Ronin Equity Partners [Member]

Subsequent Event [Line Items]

Borrow amount

$ 37,500

Subsequent Event [Member] | Cohen Enterprises Inc [Member]

Subsequent Event [Line Items]

Borrow amount

$ 50,000

Subsequent Event [Member] | Consulting Agreement [Member] | John Dorsey [Member]

Subsequent Event [Line Items]

Number of shares issued

200,000

Settlement description

the services under the agreement, the Company agreed to pay Dorsey $6,000 a month and issued Dorsey a total of 200,000 shares, which vest in accordance with the following vesting schedule; a) 50,000 shares vest upon the execution of the Agreement, b) 75,000 shares vest upon the three (3) month anniversary of the Agreement, and c) 75,000 shares vest upon the six (6) month anniversary of the Agreement (the “Dorsey Consulting Shares”).

Subsequent Event [Member] | Consulting Agreement [Member] | G&P General Consulting [Member]

Subsequent Event [Line Items]

Number of restricted common shares issued

250,000

Number of additional restricted common shares issued

500,000

Share price

$ 0.28

Number of restricted common shares issued, value

$ 70,000

Subsequent Event [Member] | Consulting Agreement [Member] | Luca Consulting, LLC [Member]

Subsequent Event [Line Items]

Number of restricted common shares issued

500,000

200,000

Share price

$ 0.1975

$ 0.28

Number of restricted common shares issued, value

$ 98,750

$ 56,000

Agreement payable in cash

$ 5,000

$ 15,000

Consulting agreement description

(a) $5,000 on the signing of the agreement; (b) $5,000 on the tenth of each month throughout the remainder of the agreement. The Service Agreement includes customary indemnification obligations requiring the Company to indemnify Luca and its affiliates with regard to certain matters.

Subsequent Event [Member] | Consulting Agreement [Member] | First Level Capital [Member]

Subsequent Event [Line Items]

Number of restricted common shares issued

250,000

Number of additional restricted common shares issued

250,000

Share price

$ 0.28

Number of restricted common shares issued, value

$ 70,000

Agreement payable in cash

$ 60,000

Consulting agreement description

(a) $60,000 on the signing of the agreement; (b) $60,000 on the approval by the Company. The Service Agreement includes customary indemnification obligations requiring the Company to indemnify First Level and its affiliates with regard to certain matters.

Subsequent Event [Member] | Consulting Agreement [Member] | Zvonimir Moric Consulting [Member]

Subsequent Event [Line Items]

Number of restricted common shares issued

150,000

Share price

$ 0.1975

Number of restricted common shares issued, value

$ 29,625

Subsequent Event [Member] | Underwriting Agreement [Member]

Subsequent Event [Line Items]

Exercise price per share

$ 0.375

Subsequent Event [Member] | Underwriting Agreement [Member] | Warrant [Member]

Subsequent Event [Line Items]

Number of warrants to purchase of common stock

42,000

Subsequent Event [Member] | Consulting Agreements [Member]

Subsequent Event [Line Items]

Share price

$ 0.4209

Issuance of common stock for cash

$ 84,180

SCHEDULE OF SHARE PURCHASE AGRE

SCHEDULE OF SHARE PURCHASE AGREEMENT (Details) - Share Purchase Agreement [Member]	Apr. 28, 2024 USD ($) shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Initial Stated Value of Preferred Stock to be issued by installment	$ 2,750,000
Warrants to be issued | shares	4,800,000
Aggregate Purchase Price by installment	$ 2,500,000
Purchaser [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Initial Stated Value of Preferred Stock to be issued by installment	$ 2,750,000
Warrants to be issued | shares	4,800,000
Aggregate Purchase Price by installment	$ 2,500,000
Initial Closing [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Initial Stated Value of Preferred Stock to be issued by installment	$ 550,000
Warrants to be issued | shares	3,300,000
Closing Date	Initial Closing Date
Aggregate Purchase Price by installment	$ 500,000
Initial Closing [Member] | Purchaser [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Initial Stated Value of Preferred Stock to be issued by installment	$ 550,000
Warrants to be issued | shares	3,300,000
Closing Date	Initial Closing Date
Aggregate Purchase Price by installment	$ 500,000
Second Closing [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Initial Stated Value of Preferred Stock to be issued by installment	$ 275,000
Closing Date	On or before June 30, 2024
Aggregate Purchase Price by installment	$ 250,000
Second Closing [Member] | Purchaser [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Initial Stated Value of Preferred Stock to be issued by installment	$ 275,000
Closing Date	On or before June 30, 2024
Aggregate Purchase Price by installment	$ 250,000
Third Closing [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Initial Stated Value of Preferred Stock to be issued by installment	$ 825,000
Warrants to be issued | shares	1,500,000
Closing Date	On or before June 30, 2024
Aggregate Purchase Price by installment	$ 750,000
Third Closing [Member] | Purchaser [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Initial Stated Value of Preferred Stock to be issued by installment	$ 825,000
Warrants to be issued | shares	1,500,000
Closing Date	On or before June 30, 2024
Aggregate Purchase Price by installment	$ 750,000
Fourth Closing [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Initial Stated Value of Preferred Stock to be issued by installment	$ 1,100,000
Closing Date	Such date as is no later than 180 days (the “Fourth Closing Date”) after the shares of Common Stock issuable in respect of the Series B Preferred Stock sold in each of the Initial Closing, Second Closing, the Third Closing, and the Fourth Closing have been registered under the Securities Act of 1933, as amended (the “Securities Act”), subject to any limitations pursuant to Rule 415
Aggregate Purchase Price by installment	$ 1,000,000
Fourth Closing [Member] | Purchaser [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Initial Stated Value of Preferred Stock to be issued by installment	$ 1,100,000
Closing Date	Such date as is no later than 180 days after the shares of Common Stock issuable in respect of the Series B Preferred Stock sold in each of the Initial Closing, Second Closing, the Third Closing, and the Fourth Closing have been registered under the Securities Act, subject to any limitations pursuant to Rule 415
Aggregate Purchase Price by installment	$ 1,000,000

SCHEDULE OF FOREIGN CURRENCY TR

SCHEDULE OF FOREIGN CURRENCY TRANSLATION AND TRANSACTION (Details)	Jun. 30, 2024
Period End Spot Rate [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Period end spot rate	1
Period End Spot Rate [Member] | MEXICO
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Period end spot rate	0.54
Average Rate [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Period end spot rate	1
Average Rate [Member] | MEXICO
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Period end spot rate	0.58

SCHEDULE OF OPTIONS OUTSTANDING

SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Weighted Average Outstanding	$ 0.69	$ 0.73	$ 1.10
Outstanding Options	2,366,667	2,650,000	1,250,000
Weighted Average Exercise Price, Exercisable	$ 0.61	$ 0.73	$ 1.10
Exercisable Options	1,979,167	1,812,500	133,333
Range One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Weighted Average Outstanding	$ 1.10	$ 1.10
Outstanding Options	1,116,667	1,400,000
Options Term	4 years 10 days	4 years 3 months 10 days
Weighted Average Exercise Price, Exercisable	$ 1.10	$ 1.10
Exercisable Options	729,167	562,500
Range Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Weighted Average Outstanding	$ 0.32	$ 0.32
Outstanding Options	1,250,000	1,250,000
Options Term	4 years 6 months	5 years
Weighted Average Exercise Price, Exercisable	$ 0.32	$ 0.32
Exercisable Options	1,250,000	1,250,000

SCHEDULE OF OPTIONS FAIR VALUE

SCHEDULE OF OPTIONS FAIR VALUE ASSUMPTIONS (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Dividend yield	0%	0%
Maximum [Member]
Fair value of common stock on measurement date	$ 0.99	$ 1
Risk free interest rate	3.83%	3.83%
Volatility	232.05%	232.05%
Expected term	6 years	6 years
Minimum [Member]
Fair value of common stock on measurement date	$ 0.29	$ 0.32
Risk free interest rate	3.30%	3.30%
Volatility	92.54%	92.54%
Expected term	3 years 6 months	3 years 6 months

SCHEDULE OF WARRANTS OUTSTANDIN

SCHEDULE OF WARRANTS OUTSTANDING AND EXERCISABLE (Details)	6 Months Ended
	Jun. 30, 2024 $ / shares shares
Schedule Of Warrants Outstanding And Exercisable
Weighted Average Exercise Price Exercised | $ / shares	$ 0.55
Outstanding and Vested Warrants Ending balance | shares	6,185,000
Outstanding and Vested Warrants Expected Term	4 years 3 months 18 days

SCHEDULE OF WARRANTS FAIR VALUE

SCHEDULE OF WARRANTS FAIR VALUE ASSUMPTIONS (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Dividend rate	0%	0%
Minimum [Member]
Fair Value of Common Stock on measurement date	$ 0.29	$ 0.32
Risk-free interest rate	3.30%	3.30%
Volatility	92.54%	92.54%
Expected term	3 years 6 months	3 years 6 months
Maximum [Member]
Fair Value of Common Stock on measurement date	$ 0.99	$ 1
Risk-free interest rate	3.83%	3.83%
Volatility	232.05%	232.05%
Expected term	6 years	6 years
Warrant [Member]
Dividend rate	0%	0%
Expected term	5 years	5 years
Warrant [Member] | Minimum [Member]
Fair Value of Common Stock on measurement date	$ 0.21	$ 0.37
Risk-free interest rate	2.95%	2.95%
Volatility	81.92%	81.92%
Warrant [Member] | Maximum [Member]
Fair Value of Common Stock on measurement date	$ 0.73	$ 0.97
Risk-free interest rate	4.38%	4%
Volatility	239.06%	169.22%

DEPOSITS (Details Narrative)

DEPOSITS (Details Narrative) - USD ($)	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule Of Warrants Outstanding And Exercisable
Deposit	$ 16,942	$ 16,942	$ 16,942
Balance amount	$ 16,942	$ 16,942